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CHAPTER 1
INTRODUCTION

1.1 Pre-invasive lesions of the breast
The normal human breast is a complex organ composed of thousands of small
clusters of glands called lobules that are lined by specialized epithelial cells which
produce milk. The milk is drained by collecting ducts that join to form larger ducts finally
terminating in the nipple.

The collecting duct branches extensively and ends into

terminal ductal lobular unit (TDLU), the smallest functional unit of the breast. A typical
terminal ductal lobular unit is composed of a lobule and a terminal duct with its multiple
end ductules or acini. The duct and TDLU are lined by two layers of cells, the innermost
luminal epithelial layer and outer layer of myoepithelial cells. Uncontrolled proliferation
of neoplastic epithelial cells in the ducto-lobular network gives rise to preinvasive
lesions.

Histologically, the preinvasive lesions are classified into two categories:

lobular and ductal subtypes. Although both types of lesions arise in the TDLU, they
differ in the cell morphology. The lobular lesions consist of small, non polarized, loosely
cohesive cells that resemble luminal cells of breast acini, while the ductal lesions
consist of cells that are more similar to the cells of normal breast ducts.

The

preinvasive lesions culminating to lobular neoplasia are atypical lobular hyperplasia
(ALH) and lobular carcinoma in situ (LCIS) whereas flat epithelial atypia (FEA), atypical
ductal hyperplasia (ADH) and ductal carcinoma in situ (DCIS) constitute the preinvasive
lesions of ductal subtype. In US, majority of newly diagnosed cases (approximately
80%) of preinvasive and invasive breast cancer are of ductal type (Sgroi 2010).
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1.2 Ductal carcinoma in situ
Ductal carcinoma in situ (DCIS) results from proliferation of the transformed epithelial
cells in the ducts of the breast. The malignant epithelial cells accumulate in the lumen
of the duct but remain confined therein without breaching the basement membrane
(Pinder and Ellis 2003).

This in situ, non-invasive stage may further progress to

invasive breast cancer in some patients.

The proportion of DCIS lesions that will

progress to invasive disease is unpredictable and the latency of disease progression is
highly variable. There has been a gradual change in the perception about DCIS in the
scientific community and DCIS is now recognized as a separate specific pathologic
entity from invasive ductal cancer (IDC) and is considered as an immediate non-obligate
precursor to IDC (Schnitt, Silen et al. 1988; Allred, Mohsin et al. 2001) .

1.2.1 Epidemiology of DCIS
Prior to 1980, DCIS was rarely detected and was only usually diagnosed when it
formed a large palpable mass in the breast.

With the introduction of nationwide

mammographic screening, DCIS became the most rapidly increasing subset of breast
carcinomas. The incidence of DCIS rose from 1.87 per 100,000 women in 1973-1975
to 32.5 per 100,000 in 2005 (Virnig, Wang et al. 2010). Figure 1.1 represents the trends
in incidence of DCIS in the pre and post mammography era. Currently, more than
60,000 patients are diagnosed with DCIS each year in the US (Lari and Kuerer 2011).
At present, DCIS accounts for 20-45% of all newly detected cancers in females
undergoing breast screening (Sakorafas, Farley et al. 2008). The incidence of DCIS in
women younger than 30 years is rare and the incidence is low in those younger than 40

3
years. The risk of getting DCIS progressively increases from age 40 to 50 years and
then more slowly after age 50 years and stabilizes after age 60 years.

1.2.2 Diagnosis of DCIS
DCIS is usually an asymptomatic disease and is most commonly detected as
microcalcifications in screening mammography. These calcifications may manifest as
fine linear branching, pleomorphic, clustered or rounded in appearance (Evans 2003).
The mammographic findings are then further confirmed with biopsy of the breast tissue.
In some cases, calcifications may develop only in part of the DCIS lesion and a large
part may be occult in mammography. Hence, mammography may underestimate the
pathologic extent of disease, especially in patients with multifocal disease. Magnetic
resonance imaging (MRI) is more sensitive in diagnosing DCIS than mammography
(92% versus 56%) and the number of missed DCIS cases with MRI is far fewer than
those missed with mammography (Kuhl, Schrading et al. 2007). However, the use of
MRI alone in diagnosis is not advocated because of its moderate specificity in detection
of DCIS (Lehman 2010).

1.2.3 Classification of DCIS
Early attempts to classify DCIS were based on gross and histological features of the
lesions such as size and shape of cells, microscopic growth pattern, rate of growth and
degree of cellular necrosis. The most aggressive form was referred to as ‘comedo-type’
with characteristic central necrosis and surrounding large, irregular proliferating cells
(Figure 1.2).

All other DCIS lesions were classified as ‘non-comedo’ type as the
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structure was less necrotic and the cells look smaller with more normal appearance.
These non-comedo lesions were further categorized according to their growth pattern
into following different types:

Cribriform (appearing to have small holes or pores),

papillary (appearing to have fingerlike projections), micropapillary (showing smaller
fingerlike projections) and solid (cells filling up the lumen completely). However, certain
DCIS lesions do not fit in any of the above categories and they have a more complex
growth pattern and cellular features. These were collectively grouped as ‘mixed type’.
The histomorphological classification described above has limited clinical utility as it
does not address intra-tumoral diversity of DCIS lesions. This traditional classification
focuses on cellular arrangement and does not reflect the biologic potential of individual
lesion.

More recent classification approaches are based on numerical scoring and

nuclear grade, which reflect cell differentiation and growth rate. In this system, the
DCIS lesions are graded as well differentiated (grade1), moderately differentiated
(grade 2) and poorly differentiated (grade 3) depending upon the extent of differentiation
of cells (Figure 1.2). It is important to note that there is no accepted standard method of
grading and this classification method also has limitations with regard to intra-tumor
heterogeneity in individual DCIS cases.
In the current clinical practice, for prognosis and treatment decisions, a fairly
reproducible classification system called Van Nuys Prognostic scoring index (VNPI) is
widely used (Silverstein, Lagios et al. 1996).

VNPI scores take into account several

quantifiable parameters of DCIS. This pathologic classification combines the following
four factors: overall tumor size, clear surgical margin width, nuclear grade and age of
the patient. Scores of 1 (best) to 3 (worst) are assigned for each of the four factors and
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then summed up to give an overall VNPI score ranging from 4 to 12. Patients are then
subgrouped according to the overall score into three risk categories. Those with high
nuclear grade lesions are grouped into the worst prognostic category (group 3) and
patients having non-high-grade lesions (nuclear grade 1 or 2) are then categorized as
group 2 (intermediate group) or group 1 depending upon the presence or absence of
necrosis respectively (Figure 1.3).
1.2.4 Evolution and progression of DCIS
Presently, there are two major proposed models which aim to explain the origin and
evolution of breast tumorigenesis.

The stochastic model, also known as clonal

evolution model, postulates that any breast epithelial cell may be the target of an
initiating event and the cancer process evolves further with cumulative genetic,
epigenetic and phenotypic changes combined with selection over a period of time. The
other model namely the cancer stem cell model hypothesizes that the cell of origin may
be either a breast stem cell itself or any progenitor cell (Wicha, Liu et al. 2006; Kakarala
and Wicha 2008).
Several models have also been proposed to describe the progression of breast
carcinoma.

These models are based on epidemiological, morphological and

immunohistochemical studies. The traditional linear model of breast cancer progression
hypothesizes that the progression occurs sequentially in stages from normal epithelium
to invasive carcinoma via non-atypical and atypical hyperplasia and in situ carcinoma.
Genomic and transciptomic studies provide further support to this multistep progression
model. The classic ‘ductal’ model proposed by Wellings and co-workers suggests that
Flat Epithelial Atypia (FEA), Atypical Ductal Hyperplasia (ADH) and Ductal carcinoma in
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situ (DCIS) are non-obligate precursors of invasive ductal carcinoma (IDC).

The

postulates of this classic theory are that DCIS is a direct precursor of IDC and ADH is a
direct precursor to low grade DCIS (Wellings and Jensen 1973). Page and colleagues
proposed an alternative linear multistep model resembling the classic ‘Wellings ductal’
model and include in their model, usual ductal hyperplasia as the precursor of ADH
(Page, Dupont et al. 1985). This alternative model has been contested however in the
light of immunohistochemical and genomic findings that indicate that usual ductal
hyperplasia has a distinct immunohistochemical and molecular profile from FEA.
Other models reflect different views from these linear theories about the evolutionary
pathways of DCIS and IDC. ‘Non-linear’ and ‘branched’ models describe DCIS as a
progenitor of IDC and propose that different grades of DCIS progress to different grades
of IDC. A ‘parallel’ model of progression of DCIS and IDC has been proposed by
Sontag and Axelrod (Sontag and Axelrod 2005), which suggests that DCIS and IDC
diverge from a common progenitor cell and progress independently through different
grades in parallel. This model corresponds very well with the pathological observations
with regard to heterogeneity of DCIS and IDC lesions.

A theoretical view of intra-

lesional or inter-lesional heterogeneity in DCIS is depicted in the Figure 1.4. The DCIS
lesion may be homogenous or heterogeneous in terms of different nuclear and cell
sizes, coexisting different molecular subtypes, and genetic and epigenetic alterations
(Berman, Gauthier et al. 2010). The parallel model, however, calls into question the
rationale of doing mammographic screenings to detect IDC at an early stage and also
the current treatment strategy for DCIS to prevent the progression to IDC.
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1.2.5 Genomic analyses and expression profiling of DCIS
To date, there have not been many studies of DCIS as compared to IDC but it seems
likely that the same chromosomal regions are amplified with comparable frequencies in
DCIS as occurring in IDC. Simpson et al. showed that a loss of 16q results in low grade
DCIS whereas high grade DCIS is characterized by amplification in 17q12 region
(Simpson, Gale et al. 2005). Comparative genomic hybridization (CGH) analyses of
DCIS and IDC lesions also confirm the above findings (Buerger, Otterbach et al. 1999).
They show that low and intermediate grade DCIS are characterized by chromosomal
loss of 16q whereas 1q gain and 11q loss occur at higher frequency in intermediate
grade DCIS. High grade DCIS, however is more complex in terms of these alterations
as characterized by losses in 8p, 11q, 13q and 14q, gains in the 1q, 5p, 8q and 17q
and amplifications of 17q12 (ERBB2) and 11q13 (cyclin D1). Loss of heterozygosity
(LOH) studies in preinvasive breast lesions by O’Connel and colleagues revealed
chromosome 16q as a common LOH hot spot in ADH as well as in low grade DCIS
(O'Connell, Pekkel et al. 1998).

Molecular cytogenetic analysis by CGH of several

preinvasive and invasive breast cancer cell lines revealed that most common gains are
found at 8q, 1q, 7q, 3q and 7p and losses occur at Xp, 8p, 18q and Xq (Forozan,
Veldman et al. 1999).
Over the past few years, tremendous technological development has occurred that
has enabled researchers to interrogate the molecular events occurring at the
preinvasive stages of breast cancer.

Tissue micro-dissection coupled with high

throughput genomic and proteomic technologies have broadened our comprehension of
the biology of DCIS.

These technologies have provided useful molecular
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characterization of DCIS lesions and have identified distinct facets of premalignant
progression. Several gene expression profiling studies of DCIS have been carried out
using a combination of laser capture micro-dissection and microarrays (Ma, Salunga et
al. 2003; Schuetz, Bonin et al. 2006; Castro, Osorio et al. 2008; Vincent-Salomon,
Lucchesi et al. 2008; Emery, Tripathi et al. 2009; Muggerud, Hallett et al. 2010). Serial
analysis of gene expression found that the most dramatic transcriptome change occurs
at the transition from normal epithelium to DCIS rather than from DCIS to invasive
cancer (Porter, Lahti-Domenici et al. 2003).

This is supported by phenotypic and

genomic analyses demonstrating that the molecular heterogeneity of breast ductal
carcinomas is already established in in situ lesions (Vincent-Salomon, Lucchesi et al.
2008), and also from studies of co-existing DCIS and IDC (Castro, Osorio et al. 2008).
Increase in tumor grade and presence of necrosis have been associated with greater
gene expression variability and distinct transcriptional signatures (Adeyinka, Emberley
et al. 2002; Ma, Salunga et al. 2003). Hannemann et al. identified a gene expression
classifier of 35 genes that differed between DCIS and IDC and a panel of 43 genes
which further distinguished well and poorly differentiated DCIS (Hannemann, Velds et
al. 2006).

1.2.6 Molecular markers of DCIS
Molecular profiling is being gradually integrated with histogical observations to
improve risk stratification and for selection of appropriate therapy for patients with DCIS.
Based on combination of molecular and morphological features with genomic and
immunohistochemical data, most preinvasive and invasive lesions are stratified into
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those following either a low grade molecular pathway or a high grade molecular
pathway as depicted in Figure 1.5. The low grade molecular subtype is characterized
by loss of 16q, gains of 1q and expression of estrogen (ER) and progesterone (PR)
receptors and the lesions of this subtype are referred to as ‘luminal’. Furthermore,
depending upon the absence or presence of Her-2, they are classified as luminal A or
luminal B, respectively.

The high grade variety has gain of 11q13, loss of 13q,

amplification of 17q12 and infrequent expression of ER and PR. Lesions with these
molecular and gene expression signatures are referred to as ‘basal’ or ‘Her-2’
depending upon the absence or presence of Her-2 expression, respectively. Some of
the important molecular markers mentioned above and others that have previously been
identified in patients with DCIS are described in further detail below.
Her-2/neu:
The Her-2/neu gene encodes for an proto-oncoprotein, c-erbB2, a tyrosine kinase
receptor.

Her-2/neu amplification plays an important role in initiation rather than in

progression of ductal carcinoma (Allred, Clark et al. 1992) and its overexpression
predicts local recurrence (Han, Nofech-Mozes et al. 2012).
Estrogen receptor (ER):
Estrogen receptor (ER) expression is inversely related to the grade of DCIS lesions
(Kuerer, Albarracin et al. 2009) and targeting DCIS that express ER with tamoxifen
significantly reduces risk of subsequent breast cancer by 40%–50% (Allred, Anderson
et al. 2012).
Progesterone receptor (PR):
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Similar to ER, Progesterone receptor (PR) expression also has an inverse
relationship to nuclear grade and its presence is associated with expression of ER and
lack of comedo-necrosis in DCIS (Claus, Chu et al. 2001; Barnes, Boland et al. 2005).
Cyclin D1:
Cyclin D1 is an important regulator of cell cycle and cyclin dependent kinases.
Amplification of cyclin D1 is observed in 10-18% cases of DCIS (Simpson, Quan et al.
1997; Vos, Ter Haar et al. 1999). There have been conflicting reports on the correlation
between expression of cyclin D1 and ER (Oh, Choi et al. 2001; Lebeau, Unholzer et al.
2003). Studies also report that there is no correlation between cyclin D1 expression
and risk of local recurrence (Millar, Tran et al. 2007).
c-myc:
c-myc is a proto-oncogene that regulates cell growth and proliferation. Although
increased c-myc expression is associated with poor prognosis in IDC, its role in
preinvasive lesions is not clear.

There have been conflicting reports regarding the

amplification of c-myc gene in the premalignant lesions of the breast.

No c-myc

amplification was observed in DCIS in two independent studies (Vos, ter Haar et al.
1999; Robanus-Maandag, Bosch et al. 2003), whereas other groups reported c-myc
amplification in the DCIS lesions (Watson, Safneck et al. 1993; Aulmann, Bentz et al.
2002). Altintas et al. reported that high expression of c-myc in DCIS did not predict
local recurrence (Altintas, Lambein et al. 2009).
Bcl-2:
Bcl-2 is a protein regulating apoptosis and has been shown to be an independent
prognostic marker in early stages of breast carcinoma.

It is present in the whole
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continuum of breast lesions from FEA, ADH to well-differentiated DCIS (Siziopikou,
Prioleau et al. 1996; Meteoglu, Dikicioglu et al. 2005).

The expression of Bcl-2

gradually decreases as lesions become more aggressive (Mustonen, Raunio et al.
1997).
P53:
P53 is a tumor suppressor gene and regulates transcription and repression of a
number of genes.

Inactivating mutations of p53 have been observed in a large

percentage (40%) of high grade DCIS, whereas low grade DCIS do not exhibit any
alterations, and the frequency of these mutations is very low (5%) in the intermediate
grade lesions. (Walker, Jones et al. 1997; Done, Eskandarian et al. 2001).
Ki67:
Ki67 is a cell cycle associated nuclear protein and is commonly used as a
proliferation marker. The expression levels of Ki67 in DCIS have been reported as 1015% (Barnes, Khavari et al. 2005). ADH and well differentiated DCIS lesions generally
have low expression of ki67 whereas poorly differentiated lesions have high ki67
expression levels.
E-cadherin:
E-cadherin is a tumor suppressor gene. It is an important molecular marker for
differential diagnosis of low grade DCIS, which stains characteristically positive for Ecadherin, from the lobular lesions that are exclusively negative for E-cadherin (Vos,
Cleton-Jansen et al. 1997; Jacobs, Pliss et al. 2001).
Vascular Endothelial Growth Factor (VEGF):

12
VEGF is an angiogenic factor and high expression levels in DCIS have been
observed (Viacava, Naccarato et al. 2004). Hieken et al. suggest that increase in VEGF
expression correlates with the biologic aggressiveness of DCIS lesions (Hieken, Farolan
et al. 2001). E-cadherin has also been shown to be associated with the expression
levels of VEGF-A and VEGF-C that contribute to angiogenic process in DCIS (Gotte,
Kersting et al. 2007).
A direct positive relationship has been observed for the expression of ER, PR, and
Bcl-2 (Provenzano, Hopper et al. 2003). Ringberg et al. (Ringberg, Anagnostaki et al.
2001) suggest that a molecular signature with lack of ER and PR, Her-2 overexpression, accumulation of p53, and high ki67 expression is a strong predictor of local
recurrence rate in DCIS. In a retrospective study of DCIS cases, DCIS lesions that
were positive for p16, COX-2, and Ki67 expression were significantly associated with
risk of subsequent invasive cancer whereas DCIS lesions that either lacked ER but
were positive for ERBB2 and Ki67 or that lacked COX2 and were positive for p16 and
Ki67 were associated with recurrence of DCIS (Kerlikowske, Molinaro et al. 2010).
There are conflicting reports on the status of other molecular markers such as TGFβ,
p16, p27, p21 and it is currently hard to interpret the roles of these molecules in the
context of DCIS progression. Efforts are ongoing in the field towards deciphering the
molecular events associated with progression of DCIS. Lu et al. identified that 14-3-3sigma in conjunction with ERBB2 promotes the progression of DCIS to IDC (Lu, Guo et
al. 2009). Qi et al. analyzed micro-RNA expression patterns in the preinvasive and
invasive lesions of the breast. They found a consistent increase in the expression of
miR-21 along with its targets (PTEN, PCCD4 and TMI) at each successive stage (Qi,
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Bart et al. 2009).

A comprehensive systematic review of the studies done on the

biological markers of DCIS over the past 10 years has been compiled by Lari and
Kuerer (Lari and Kuerer 2011). The authors concluded that there is an unmet need to
identify important prognostic and predictive markers in DCIS and the study of
biomarkers is still in its infancy in DCIS as compared to IDC.
1.3 Goals and significance of the present study
The goal of most expression studies in DCIS has been to characterize molecular
features of the lesions that are likely to progress to invasive cancer from those that
remain indolent.

Most research efforts have focused towards understanding the

progression of DCIS to invasive breast cancer; however, current knowledge of earlier
events in the breast tumorigenesis remains limited.

It is imperative to identify the

underlying molecular and genetic changes that drive transition from normal breast
epithelium to preinvasive lesions of DCIS.

In the present study, our aim was to

determine and compare the gene expression profiles of normal mammary epithelial
cells and different DCIS models. Results from this study may help in elucidating key
genes and pathways involved in the premalignant process and may help to establish
clinical biomarkers and define constituents of networks and pathways that contribute to
the DCIS pathology.
We hypothesize that there will be a common set of genes highly differentially
expressed between normal mammary epithelial cells and different models of DCIS, and
that the products of these genes may be potential targets for preventing the
premalignant progression.
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Specific Aim 1: To determine the expression changes that are common to multiple DCIS
models in comparison to normal mammary epithelial cells by whole genome microarray
analysis.
Specific Aim 2: To validate the results obtained from microarray studies using other
platforms such as next generation sequencing, real time polymerase chain reaction
(qRT-PCR) and western blotting.
Specific Aim 3: To characterize the molecular pathways of selected genes and their role
in premalignant progression.
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Figure 1.1: Trends in the incidence of ductal carcinoma in situ (DCIS) and
invasive breast cancer (1975-2005). The incidence of DCIS rose from 1.87 per
100,000 women in 1973-1975 to 32.5 per 100,000 in 2005 (Adapted from Virnig et al.
JNCI, 2010)
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Figure 1.2: Classification scheme of DCIS lesions. (Upper Panel) Based on
histomorphological features, DCIS lesions are categorized into following types A)
Comedo B) Cribriform C) Solid D) Micropapillary E) Papillary F) Mixed; (Lower Panel)
Based on the extent of differentiation of cells, the lesions are graded as well
differentiated (grade1), moderately differentiated (grade 2) or poorly differentiated
(grade 3). (Adapted from Allred DC, JNCI Monographs, 2010)
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nuclear grades 1 or 2

nuclear grade 3
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Necrosis absent
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Necrosis present
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Figure 1.3: Classification of DCIS lesions by modified Van Nuys prognostic
scoring index (VNPI). VNPI score combines the following four factors: overall tumor
size, clear surgical margin width, nuclear grade and age of the patient. Patients are
grouped according to the overall score into three risk categories. Patients with high
nuclear grade lesions are grouped into the worst prognostic category (group 3) and
those with non-high-grade lesions (nuclear grade 1 or 2) are then categorized as group
2 (intermediate group) or group 1 depending upon the presence or absence of necrosis
respectively. (Adapted from Silverstein MJ, Oncologist, 1998)
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Figure 1.4: A hypothetical model depicting heterogeneity in DCIS lesions. The
DCIS lesions may be homogenous or heterogeneous based on different nuclear, cell
sizes and coexisting different molecular subtypes. The two ducts represent theoretical
heterogeneity between different DCIS patients (interlesional) or between two different
regions in a DCIS lesion in the same patient (intralesional). (Adapted from Berman et
al., Cancer Prev. Res., 2010)
.
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Figure 1.5: Classification of invasive ductal breast cancer based on distinct
genetic and molecular profiles. Lesions are stratified into following either low grade
molecular pathway or high grade molecular pathway. A) The low grade lesions are
characterized by loss of 16q, gains of 1q and expression of estrogen (ER) and
progesterone (PR) receptors. B) The high grade lesions have gain of 11q13, loss of
13q, amplification of 17q12 and infrequent expression of ER and PR. The luminal A
and luminal B subtypes mainly follow the low grade like gene-expression pathway and
are generally indolent whereas high grade like pathway is followed by the aggressive
subtypes like Her-2 and basal. (Adapted from Sgroi DC, Annu. Rev. Pathol. Mech. Dis.,
2010)
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CHAPTER 2

MATERIALS AND METHODS

2.1 MATERIALS
Disulfiram and Riluzole were generous gifts from Drs Angelika Burger and David
Gorski respectively (Karmanos Cancer Institute, Detroit, MI).

Ham’s F-12 nutrient

mixture (F-12), Dulbecco’s modified Eagles medium/Ham’s F-12 nutrient mixture
(DMEM/F12), bovine serum albumin (BSA), hydrocortisone, dimethyl sulfoxide (DMSO),
4-hydroxybenzaldehyde and valproic acid were purchased from Sigma (St. Louis, MO).
Phosphate-buffered saline (PBS), horse serum, epithelial growth factor (EGF), insulin,
and 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and Trizol®
were purchased from Invitrogen (Carlsbad, CA).

Mammary Epithelial Media 171

(M171) and Mammary Epithelial Growth Factor Supplement were from Cascade
Biologics (Portland, OR). Fetal bovine serum (FBS) was from Hyclone (Logan, UT).
Trypsin/EDTA solution, and penicillin-streptomycin were from Cellgro (Herndon, VA).
Cultrex™ rBM was from Trevigen (Gaithersburg, MD). Total RNA prepared from human
mammary epithelial cells was obtained from Cell Applications (San Diego, CA). Primary
antibodies used for western blotting were mouse anti-GAPDH (EMD Chemicals,
Darmstadt, Germany) and goat anti-ALDH5A1 (sc-70007, Santa Cruz Biotechnology,
Santa Cruz, CA), with horseradish peroxidase-conjugated secondary antibodies and
enhanced chemiluminescence detection as previously described (Li, Chow et al. 2010).
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2.2 METHODS
2.2.1 Cell Lines and Culture
MCF10A and MCF10.DCIS cell lines were obtained from the Cell Lines Resource
(Karmanos Cancer Institute, Detroit, MI) and maintained as monolayers in DMEM/F12
containing 5% horse serum, 0.5 µg/ml hydrocortisone, 10 µg/ml insulin, 50 U/ml
penicillin, and 50 µg/ml streptomycin (and 5 ng/ml EGF only for MCF10A) at 37°C and
5% carbon dioxide as previously described (Li, Chow et al. 2010).

SUM102 and

SUM225 cell lines were a generous gift from Dr. Stephen Ethier (Karmanos Cancer
Institute, Detroit, MI) and were maintained as monolayers in Ham’s F-12 containing 5%
fetal bovine serum, 5 µg/ml insulin and 1 µg/ml hydrocortisone, 50 U/ml penicillin, and
50 µg/ml streptomycin.
In the in vitro three dimensional (3D) overlay culture with reconstituted basement
membrane (rBM) protocol, single cells were seeded onto culture dishes previously
coated with rBM (Cultrex®) and were overlaid with media containing 2% rBM (assay
medium) as described previously (Li, Mullins et al. 2008; Sameni, Cavallo-Medved et al.
2009; Li, Chow et al. 2010).

The 3D rBM overlay culture system described was

modified to provide uniform culture conditions for all the cell lines by use of M171 media
with Mammary Epithelial Growth Factor Supplement. The final supplemented media
contained bovine pituitary extract, 0.4% v/v; bovine insulin, 5 µg/ml; hydrocortisone, 0.5
µg/ml; and recombinant human epidermal growth factor, 3 ng/ml, 50 U/ml penicillin and
50 µg/ml streptomycin. In brief, for 3D culture, each 60-mm dish was coated with 200 µl
of ice-cold rBM and incubated at 37°C for 20 minutes to allow the rBM to solidify. A
trypsinized, single cell suspension containing 1x106 cells in the supplemented 171M
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medium with 2% (v/v) rBM was added dropwise on top of the coated plate and
incubated at 37°C for 30 minutes to let the cells attach to the rBM. Then, 5 ml of the
assay medium were added, and the cells were cultured at 37°C and 5% CO2. The
medium was changed every 4 days.

2.2.2 Harvest of 3D structures
MCF10A, MCF10.DCIS, SUM102 and SUM225 cells were grown in 3D rBM overlay
culture for 12 days with change of media every 4 days. Structures were harvested from
rBM by repeated washes with ice-cold PBS supplemented with 5 mM EDTA. In brief,
after the removal of culture media, the structures were washed once with cold PBS and
then scraped using a rubber policeman in ice-cold PBS containing 5mM EDTA. The
resulting gel-sol mixture of structures and rBM in PBS was then collected from the
culture dishes into 15-ml Falcon tubes, and incubated on ice with gentle rocking for 45
minutes to allow solubilization of rBM.

The structures were then pelleted by

centrifugation at 100 x g for 5 minutes. After removal of the supernatant, the pellet was
then washed in PBS-EDTA and the above steps were repeated for the final collection of
structures in the pellet.

2.2.3 RNA extraction and purification
Total RNA was extracted from MCF10A, MCF10.DCIS, SUM102 and SUM225
samples using a combination of TRIZOL

TM

and ethanol precipitation.

In brief, the

harvested structures of MCF10A, MCF10.DCIS, SUM102 and SUM225 were lysed for
extraction of RNA by adding 1 ml TrizolTM per 60-mm culture dish. Each lysate was
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passed through a sterile 1 ml pipette tip several times and 0.2 ml of chloroform was
added followed by vigorous shaking by hand for 15 seconds. After incubation at room
temperature (RT) for 2-3 minutes, the samples were centrifuged at 12,000 x g for 15
minutes at 4°C, again followed by incubation for 2-3 minutes at RT. The upper aqueous
phase thus obtained was then transferred to a new tube and 0.5 ml of isopropanol was
added, mixed and the samples were incubated for 10 minutes at RT and then
centrifuged at 12,000 x g for 10 minutes at 4oC. Following removal of supernatant, the
RNA pellet was washed with 80% ethanol. The samples were vortexed for 10 seconds
to dislodge the RNA pellet from the side of the tube and then centrifuged for 5 minutes
at 7,500 x g at 4°C. The supernatant was discarded and the RNA pellet was air dried
for 10 min. The pellet was then dissolved in 50µl RNase free water by passing the
solution through a sterile 200 µl pipette tip and was incubated for 15 minutes at 55-60oC
to facilitate complete dissolution. An additional purification step was included in the
protocol to ensure elimination of any genomic DNA by an on-column DNase treatment
of all the RNA samples using the RNase-free DNase Kit (from Qiagen). The integrity
and quantity of RNA in the samples was determined using NanoDrop 1000
spectrophotometer (Thermo Fisher Scientific, Waltham, MA) and Agilent 2100
Bioanalyzer (Agilent Technologies).

2.2.4 Differential interference contrast (DIC) imaging
MCF10A, MCF10.DCIS, SUM102 and SUM225 cells were grown on 12 mm Cultrexcoated round coverslips and cultured in 24-well plates. Coverslips were briefly washed
with PBS at 37°C and incubated in 4% paraformaldehyde, pH 7.5 in PBS for 20 minutes
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to fix the cellular structures followed by 3x washes with 0.75% glycine in PBS. Then the
coverslips were placed in a 35-mm dish with PBS and imaged with a confocal
microscope (LSM 510; Zeiss) using 10x objective as described (Li, Mullins et al. 2008).

2.2.5 Imaging and quantification of structures
The structures were fixed and imaged as described above. Tile-scan mode was
used to obtain a 4 × 4 phase contrast tile image covering the entire area of the
coverslip. The images were then converted into tagged image file (.tif) files using the
software provided by Zeiss. The diameters of the structures were measured from at
least 100 structures for each sample using Adobe Photoshop version CS2 software
(Adobe Systems, Mountain View, CA).

2.2.6 Affymetrix microarray analysis
Specific protocols as described in the GENECHIPTM expression analysis technical
manual were followed.

RNA was labeled using Affymetrix's standard one-cycle

amplification and labeling protocol. The labeled cRNA was then hybridized to Affymetrix
Human U133A 2.0 GeneChips, which were scanned using a GeneChip Scanner. The
raw array data was processed by Affymetrix GeneChip Operating Software (GCOS) to
obtain detection calls and signal values. Each complete probe array image was stored
in a separate data file.

2.2.7 Pathway analysis
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The probe sets differentially expressed in the three DCIS samples versus MCF10A
samples were used for network analysis. Data sets containing probe set identifiers and
fold changes were uploaded into Ingenuity’s software [Ingenuity Pathway Analysis
(IPA); http:// www.ingenuity.com. The IPA program searches the Ingenuity Pathway
Knowledge Base for interactions (known from the literature) between the uploaded
genes and all other genes in the database and generates a series of networks. Fisher’s
exact t-test was used to assign statistical significance and each network’s score
displayed as -log (p value).

The common differentially expressed genes from mRNA-

Seq data were also uploaded to WEB-based GEne SeT AnaLysis Toolkit (WebGestalt)
to seek the associated significant pathways.

2.2.8 Next generation sequencing
Libraries of template molecules for high throughput DNA sequencing were prepared
using Illumina mRNA Sequencing Sample Preparation Kit. First, using Sera-Mag oligo
(dT) beads, mRNA molecules were purified from total RNA. Then the purified mRNA
samples were fragmented under elevated temperature conditions. Subsequently, first
strand cDNA synthesis was done from the cleaved RNA fragments using reverse
transcriptase and random primers. This was followed by second strand synthesis using
DNA polymerase I and RNaseH (using SuperScript II from Invitrogen). These cDNA
fragments were then subjected to repair end process with T4 DNA polymerase and
Klenow. The 3’ ends were then adenylated to prepare for adapter ligation. After paired
end ligation of adapters, the samples were purified on 1.2% agarose recovery
FlashGelTM. The library of products of desired size (150-200bp) was then selected for
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further enrichment with 15 cycles of polymerase chain reaction (PCR) amplification.
After validation of library using DNA 1000 chip (on Agilent Technologies 2100
Bioanalyzer), the samples were run on an Illumina Genome Analyzer GAIIx (Illumina,
San Diego CA, USA) for 76 cycles for sequencing. All libraries were subject to singleend sequencing. Image analysis and base calling were performed using the Firecrest
and Bustard modules of genome analyzer pipeline software (Illumina Pipeline software
v. 1.6.0).

Sequencing reads were aligned to human reference genome (hg18).

Alignments were performed with Novoalign (Novocraft Technologies SdnBhd, v.
2.05.43) using default parameters and only unique alignments were considered for
further analysis.

2.2.9 Genomatix analysis
2.2.9.1 Clustering: The next generation sequencing (NGS) analyzer from Genomatix
(www.genomatix.de) was applied to cluster the alignments based on the distribution of
aligned reads. NGS analyzer parameters were set as following: (1) the size of sliding
window as 100bp, (2) the minimum number of reads per cluster (τ) were calculated from
the dataset applying a Poisson distribution.
2.2.9.2

Gene ontology pathway analysis: The differentially expressed genes were

uploaded to Genomatix Pathway System (GePS) for gene ontology and canonical
pathway analysis. GePS uses information extracted from public and proprietary
databases to display canonical pathways or to create and extend networks based on
literature data. The output (term of gene ontology or canonical pathway) is coupled with
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a p-value.

By default, P-value < 0.05 is used as threshold to define significantly

enriched terms.
2.2.9.3 Common framework mining and enrichment analysis: Frameworker (Genomatix)
was employed to mine common framework of elements from a set of genes’ promoter
sequences. These elements are usually transcription factor binding sites. Common
frameworks are defined as all the elements (TF sites) that occur in same order and in a
certain distance range in all (or a subset of) the input sequences. The parameters used
to mine the common frameworks were: (1) Maximum distance variance between two
elements

as

20bp

(2)

the

distance

between

two

elements

as

10-200bp.

2.2.10 Real-time quantitative PCR assay (qRT-PCR)
First-strand cDNA was synthesized from total RNA using High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Foster City, CA).

The qRT-PCR

reactions were carried out using diluted cDNA, 150 nM of each primer, and SYBR
Green master mix (Applied Biosystems, Foster City, CA) in 20 µl reactions on a
StepOnePlus™ Real-Time PCR System. Each sample was run in triplicate in separate
wells

for

the

target

gene

and

three

reference

genes:

hypoxanthine

phosphoribosyltransferase 1 (HPRT1); β-actin (ACTB); and β-glucuronidase (GUSB).
The average of three threshold cycle (Ct) values for the target and reference genes was
used to determine the level of expression relative to the control. Delta-delta Ct method
was used for data analysis.

Primer pair sequences for the genes selected for

quantification are listed in Table 2.1.
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2.2.11 Cell lysis
Cell lysates for western blotting were made in RIPA lysis buffer composed of 50 mM
Tris, 150 mM NaCl, 1 mM EDTA, 1% NP-40 and 0.5% sodium deoxycholate, pH 7.4
supplemented with protease and phosphatases inhibitors (1 mM PMSF, 1 mM sodium
orthovanadate, 1 mM sodium fluoride, 50 nM okadaic acid, 8 µg/mL aprotinin, 8 µg/mL
pepstatin and 8 µg/mL leupeptin).

2.2.12 Immunoblot analysis
Cell lysates were prepared from the harvested 3D structures by addition of lysis
buffer as described previously (Li, Chow et al. 2010). The lysates were briefly sonicated
on ice, heated at 100°C for 5 minutes, separated by SDS-PAGE, transferred to
nitrocellulose membranes for immunoblotting. The blots were quantified using Fujifilm
LAS-3000 System.

2.2.13 Cell viability and proliferation assays
The 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) dye
reduction assay in 96-well microplates was used to determine cell viability. Cells (1x104)
were plated in each well previously coated with Cultrex in a total volume of 200 µl of
growth media. The wells were then treated with serial dilutions of drug and vehicle
control for 3 days.

After 3 days of drug treatment, MTT was added and further

processed for absorbance as previously described (Li, Chow et al. 2010).

After

normalizing the absorbance values for blank and vehicle controls, the data were
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analyzed using GraphPad Prism version 5.0 by non-linear regression (curve fit) to plot
sigmoid dose-response curves. The mRFP-expressing variants of MCF10.DCIS and
SUM102 were grown in 3D rBM culture on coverslips with exposure to drug or vehicle
controls for 8 days. To test for reversibility of growth inhibition, cultures were harvested
after the 8-day treatment, and the cells re-plated in fresh growth media after dilution of
the rBM. The cultures were continued in 2D without rBM for ten days in the absence of
inhibitors and then cells were counted.

2.2.14 Statistical analysis
Microarray Expression Data Analysis
Affymetrix arrays were analyzed using the manufacturer’s reader software and the
supplied scanner software. Data analysis was done in three stages. First, expression
intensities were calculated for each gene probed on the array for all hybridizations (X in
total) using the MAS5 algorithm in the Affymetrix package supplied with R-Bioconductor.
Second, the intensity values were quality controlled and normalized: quality control was
carried out by using the MAS5 P/M/A flag. Genes only ever scored as ‘A’ absent were
removed from the analysis.

All the arrays were then normalized using the

normalize.quantiles routine also from the Affymetrix package in Bioconductor. This
procedure accounted for any variation in hybridization intensity between the individual
arrays. Finally, these normalized data were imported into GeneSpring and analyzed for
differentially expressed genes. The groups of biological replicates were described to
the software and significantly differentially expressed genes determined on the basis of
t-tests and fold difference changes in expression level. For other data analyses, the
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results were plotted as the mean ± SEM. Statistical analysis was performed using
Graph Pad Prism version 5.0a (Graph Pad Software Inc., San Diego, CA). Statistical
significance was determined using Student’s t-test.
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Gene of interest
TIMP-3

Primer Sequence
Forward: ACGCTGGTCTACACCATCAAGCAGA
Reverse: GACGCGACCTGTCAGCAGGTACTGG

GFPT-1

Forward: GTTGGCACAAGGCGAGGTAGCC
Reverse: AAGGCAGGTTGTGCTGTCCACAC

S100P

Forward: CGATATTCGGGCAGCGAGGGC
Reverse: CTTTTCCACTCTGCAGGAAGCCTG

RHOB

Forward: CCGGGAGAGAGCTAGGCCGAGT
Reverse: GGATCGGCGGCTTTGTGCGTA

FOXO3

Forward: TTCGCTGGCCGCACGTCTTCAG
Reverse: GGAGAGTTGGTTATCCCGGGCCG

MET

Forward: CTTTGCCAGTGGTGGGAGCACA
Reverse: AGCGATGTTGACATGCCACTGTAA

IRS1

Forward: GGAGTGCACCCCTGAACCGC
Reverse: GGTCTTCATTCTGCTGTGATGTCCA

ALDH5A1

Forward: GCATAGCCACACCCATTCATT
Reverse: CCAACTATTCAACTCTGCCAAGAA

GLUL

Forward: CTCGCTCTCGCGGCCTAGCTTT
Reverse: CCTGAGGCAGGGACATGTACACC

GLUD1

Forward: AGCTTTGGCTTCTCTGATGACAT
Reverse: ACCCCCAAACGGCACAT

CASP2

Forward: CCCACCGTTGAGCTGTGACTACGA
Reverse: GGCTTCACCTGAAGGCAGACAGG

DUSP5

Forward: ATGACCAGGGTGGCCCAGTTGAA
Reverse: CGGAGGTCCGTCGGGAGACATT

PAK1

Forward: CAGGACAGGAGGTGGCCATTAAGC
Reverse: CCACAGCTCATCTCCCACGAGG

GFPT2

Forward: CCTGCTCCTTGCCCATAGTAAA
Reverse: CCCACTTGAAACTACTCTCTTGCA

GUSB

Forward: CCAAAAAGTGCAGCGTTCCT
Reverse: ACCTGGTTTCATTGGCAATCTT

ACTB

Forward: ACCGAGCGCGGCTACA
Reverse: CTTAATGTCACGCACGATTTCC

HPRT-1

Forward: CGTCTTGCTCGAGATGTGATG
Reverse: GAGCACACAGAGGGCTACAATG

Table 2.1: Primer pair sequences of genes quantified for expression levels by real
time PCR. Specific primer pairs for the candidate genes were designed based on
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sequences from Ref-Seq and meeting the following criteria: amplicon length: 50-150
bases; optimal primer length: 20 bases; melting temperature (Tm): 58-60oC; percentage
of GC content: 30-80%; no more than 2 G/C residues in the last 5 nucleotides at the 3’
end and one of the primer in the pair should span exon-exon junction. The specificity of
the primers was then determined by a National Center for Biotechnology Information
Blast search and University of California, Santa Cruz (UCSC) in silico PCR tool.
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CHAPTER 3

WHOLE GENOME EXPRESSION ANALYSIS BY MICROARRAY REVEALS A
COMMON SET OF GENES HIGHLY DIFFERENTIALLY EXPRESSED IN DIFFERENT
MODELS OF DCIS IN COMPARISON TO NORMAL MAMMARY EPITHELIAL CELLS

3.1 BACKGROUND AND RATIONALE

Global analysis of gene expression by microarrays has been extensively used in
studying invasive breast cancer.

This approach is now being increasingly used to

advance the understanding of premalignant breast disease as well. Microarrays provide
gene expression information in a high throughput manner and thus provide
unprecedented opportunities to identify the unique transcriptional fingerprint associated
with each stage of the disease progression.
Here, we employed Affymetrix microarrays to identify transcriptional signatures of
normal mammary epithelial cells and DCIS samples of different origins to elucidate
candidate genes that may be contributing to premalignant progression. We have used
MCF10A cell line as a model for non-tumorigenic human mammary epithelial cells
hereinafter referred to as ‘normal’. MCF10A cells are a spontaneously immortalized
human breast epithelial line exhibiting normal phenotype by most criteria (Debnath,
Muthuswamy et al. 2003).

For instance, MCF10A cells do not form xenografts in

immunodeficient mice (Soule, Maloney et al. 1990), and they model normal mammary
epithelia as they form acini with apicobasal polarity and generate functional glandular
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structures when grown in three-dimensional (3D) culture in reconstituted basement
membrane (rBM) (Debnath, Mills et al. 2002).

MCF10A cells were derived from a

patient with fibrocystic breast disease who underwent reduction mammoplasty (Soule,
Maloney et al. 1990). In addition to MCF10A, we employed different DCIS models of
various origins in the present study. One model of DCIS is MCF10.DCIS, which is
isogenic with MCF10A and derived by sequential passage in vitro and in vivo of lesions
that were derived from MCF10A cells transfected with H-Ras (Dawson, Wolman et al.
1996). In immunodeficient mice, MCF10.DCIS cells initially form lesions characterized
as comedo DCIS and about 50% of the mature lesions later progress to invasive ductal
carcinoma (IDC) (Miller, Santner et al. 2000; Strickland, Dawson et al. 2000). The other
two independent DCIS cell lines were derived from individual patients: SUM102 (Sartor,
Dziubinski et al. 1997) and SUM225 (Yang, Albertson et al. 2004). SUM102 cells were
isolated from a patient diagnosed with extensive ductal carcinoma in situ with areas of
micro-invasion. SUM225 cells were derived from a chest wall recurrence in a patient
previously diagnosed and treated for DCIS.
Pre-clinical therapeutic identification and development has mostly been based in
conventional cell culture systems on plastic dishes.

We have conducted all the

experiments in the present study using in vitro three dimensional (3D) organotypic
culture models with reconstituted basement membrane (rBM). The model used in our
lab is based on a 3D overlay culture system that was adapted by Brugge et al. for
analysis of oncogene-induced changes in MCF10A cells (Debnath, Muthuswamy et al.
2003).

In the 3D rBM overlay protocol, single cells are seeded onto coverslips or

culture dishes previously coated with polymerized rBM (Cultrex® or Matrigel®) and are
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overlaid with media containing 2% rBM when the cells have attached. The rationale
and advantages of using this model system are described in detail below.
The growth of mammary epithelial cells in two dimensional (2D) monolayers on
tissue culture plastic does not reproduce the molecular and morphologic features as
they exist in normal tissue microenvironment.

The 2D monolayers lack structural

architecture and thus apical-basal polarity of single cells or ductal structures formed by
populations of epithelial cells are not replicated in these models (Debnath and Brugge
2005). In contrast, the 3D cultures with rBM more closely resemble the in vivo situation
with regard to cell polarity and its environment, which in turn influence cell behavior and
gene expression.

Cancer cells grown in three dimensional (3D) matrices, such as

reconstituted basement membrane (rBM), have been proposed to exhibit responses
and resistance to drugs that are closer to those observed in vivo (Hebner, Weaver et al.
2008; Horning, Sahoo et al. 2008; Li, Chow et al. 2010). In vitro 3D culture systems
recreate the fundamental features of glandular epithelium in vivo and provide a
structurally appropriate context for studying breast cancer progression (Kim, Stein et al.
2004). Also, the heterogeneity in 3D culture may be far more realistic than homogeneity
in 2D monolayers as the 3D culture is composed of cells with different phenotypes such
as proliferating, non-proliferating and necrotic cells, which is more similar to the in vivo
situation (Kim, Stein et al. 2004). We used novel and tractable models of DCIS in an in
vitro 3D rBM overlay culture system originally developed to study morphogenesis and
oncogenesis of MCF10A cells (Debnath, Muthuswamy et al. 2003).

The 3D rBM

overlay cultures are a better mimic of the in vivo environment than cells grown on plastic
dishes (Kenny, Lee et al. 2007) and also provide a source for high quality RNA with
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avoidance of the contribution of stromal cell RNA. Thus, we employed the in vitro 3D
culture model as opposed to conventional 2D model to conduct all our experiments for
studying the premalignant progression from non-transformed mammary epithelial cells
to DCIS.

3.2 RESULTS

3.2.1 Normal mammary epithelial cells and premalignant DCIS models exhibit
phenotypic differences in 3D overlay cultures
Our lab has further developed the in vitro 3D rBM overlay culture model originally
developed in Brugge’s laboratory to study breast cancer progression. Premalignant and
malignant variants of parental MCF10A have been previously cultured in our lab in 3D
laminin-rich rBM to analyze different signaling pathways and progression events (Li,
Mullins et al. 2008). We compared 3D rBM overlay cultures of the three DCIS models
(MCF10.DCIS, SUM102 and SUM225) to parallel cultures of MCF10A cells as a model
for human mammary epithelial cells. All cultures were grown under uniform conditions
with identical growth factors and supplements. After 12 days in 3D rBM overlay culture,
the MCF10A cells form a uniform population of acinar structures as previously
described (Debnath, Mills et al. 2002; Li, Mullins et al. 2008) whereas the three DCIS
models form larger and less uniform structures (Fig. 3.1).
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3.2.2 High quality RNA yields from normal mammary epithelial cells and different
models of DCIS grown in 3D cultures
Using high quality and intact RNA is crucial for successful microarray experiments.
We first standardized the protocol for extracting RNA from cells grown in 3D culture and
optimized different experimental variables such as cell number, growth media and
culture time for obtaining adequate yields of RNA for analysis. To minimize variability
and facilitate interpretation of microarray results in an unbiased manner, we isolated
RNA from biological triplicates for each of the cell lines. The quality and integrity of all
the RNA samples were determined using the Agilent Bioanalyzer. Profiles generated
on the Bioanalyzer provide quantitative information on the concentrations and ribosomal
ratios (28S/18S). The Bioanalyzer software generates electropherograms that allow
visual inspection of RNA integrity. The RNA integrity number (RIN) takes into account
the entire electrophoretic trace and measures RNA quality on a scale of 1 to 10 with 1
being the most degraded and 10 being the most intact profile. All the RNA samples
extracted from the 3D cultures of normal mammary epithelial cells and different models
of DCIS were of high quality. The average RIN values of the RNA samples were in the
range of 8.85-9.7. All the samples conformed to the standards required for Affymetrix
microarray analysis (RIN value > 5 or 28S/18S ratio > 1.5). In one of the MCF10.DCIS
samples (sample1), RIN value was not computed by the software due to non-critical
anomaly during sample preparation.

However, considering the ribosomal ratios

28S/18S (> 1.5) the sample quality was considered to be suitable for subsequent use
for microarray experiment.

The results of RNA quality are depicted in the

electrophoresis gel image and electropherograms in Figures 3.2a and 3.2b respectively.
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3.2.3 Whole genome Affymetrix microarray identifies differentially expressed
genes
In collaboration with Applied Technology Genomics Center (at Wayne State
University) and Sanford Burnham Institute (San Diego, California), we performed
microarray analysis of the RNA samples extracted from biological triplicates described
in the section above. We employed Affymetrix GeneChip® Human Genome U133A 2.0
Arrays, which represent 14,500 well-characterized human genes.

The GeneChip®

analyzes the expression level of 18,400 transcripts and variants and is comprised of
more than 22,000 probe sets.
The gene expression profiles by hierarchical clustering for microarray data are shown
in Figures 3.3a and b. These results indicate that the three premalignant DCIS samples
cluster more closely to each other than to normal MCF10A samples. In between these
clusters the biological replicates cluster to their equivalent in all four sample types. The
reproducibility between the biological triplicates and magnitude of changes (on log2 yaxis scale) for the pair-wise comparison of MCF10.DCIS and MCF10A is illustrated in
Figure 3.4.
As hypothesized, results from Affymetrix microarray analysis reveal a number of
genes (290) which are consistently differentially expressed between MCF10A and the
three models of DCIS we tested. Of these 290 genes, 137 were up-regulated and 153
genes were down-regulated in all the three DCIS as compared to MCF10A. Using a pvalue of 0.05 and cut-off of 1.5-fold change, we obtained 157 differentially expressed
genes (Figure 3.5).

The genes up regulated more than 10- fold in DCIS included
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aldehyde dehydrogenase 5A1 (ALDH5A1); major histocompatibility complex, class II,
DQ beta 1 (HLA-DQB1); RAB25 member of RAS oncogene family, G protein-coupled
receptor 56 (GPR56); butyrylcholinesterase (BCHE); B-box and SPRY domain
containing (BSPRY); keratin 7 (KERT7); integrin beta 2 (ITGB2); fibroblast growth factor
1 (FGF1) and immediate early response 3 (IER3) whereas genes showing more than
10-fold decrease in DCIS included dual specificity phosphatase 1 (DUSP1); alcohol
dehydrogenase 1B (ADH1B); periostin (POSTN); aspartoacylase (ASPA); chemokine
(C-X-C motif) receptor 4 (CXCR4); insulin growth factor-like family member 2 (IGFL2);
podoplanin (PDPN); decorin (DCN) and nidogen 1 (NID1). The genes with largest fold
change in expression identified in the list of those differentially expressed are
summarized in Table 3.1.

3.2.4 Ingenuity pathway analysis of microarray data reveals biological pathways
and functions of differentially expressed genes
To gain an overview of biological processes in which these differentially expressed
genes are involved, we performed gene set enrichment analysis using Ingenuity
pathway analysis (IPA) software. The network-eligible IDs proceeded into the pathway
analysis by comparing the network-eligible genes with the Ingenuity Pathways Analysis
Knowledge Base (IPAKB), which is a curated database that contains numerous
scientific findings extracted from hundreds of thousands of journal articles, textbooks,
and other data sources and many canonical pathways derived from those scientific
findings. The significance (p-values) of the association between the dataset and the
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canonical pathway is measured by comparing the number of specific genes of interest
that participate in a given pathway to the total number of occurrences of those genes in
all pathway annotations that are stored in the IPAKB.

The p-value indicates the

probability that the association between the genes in the dataset and the canonical
pathway is explained only by chance.
Gene annotation and pathway analysis showed dysregulation of many important
genes and pathways.

The canonical pathways associated with these differentially

expressed genes include glutamate metabolism, PXR/RXR activation, IGF-1 signaling,
integrin signaling and fatty acid biosynthesis (Figure 3.6). The most significant network
revealed by IPA analysis showed the presence of enzymes involved in glutamate
metabolism. The pathway includes 4 focus genes namely aldehyde dehydrogenase 5
family member 1 (ALDH5A1), glutamine–fructose-6-phosphate transaminase 2
(GFPT2), glutamate dehydrogenase 1 (GLUD1), and glutamate ammonia ligase (GLUL)
(Table 3.2).
The major functions of the differentially expressed genes were related to
hematological

disease,

infection

mechanism,

cellular

development and gastrointestinal disease (Table 3.3).

development,

embryonic

Functional annotation of the

differentially expressed genes revealed enrichment of genes involved in various
processes such as cell growth and proliferation, cell-cell signaling and interaction, cell
death, cell morphology, cellular assembly and organization. The genes found to be
associated with cell growth and proliferation and cell development are ADAM
metallopeptidase with thrombospondin type 1 motif, 5 (ADAMTS5); adaptor-related
protein complex 1, sigma 2 subunit (AP1S2); ArfGAP with SH3 domain, ankyrin repeat
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and PH domain 2 (ASAP2); cyclin D1 (CCND1); cell cycle progression 1 (CCPG);
collagen, type IV, alpha 1(COL4A1); collagen, type IV, alpha 2 (COL4A2); diazepam
binding inhibitor (GABA receptor modulator, acyl-CoA binding protein) (DBI); extended
synaptotagmin-like protein 2 (ESYT2); family with sequence similarity 102, member A
(FAM102A); fibulin 1(FBLN); follistatin (FST); hemoglobin, epsilon 1(HBE1); huntingtin
(HTT); mannosidase, alpha, class 1A, member 1 (MAN1A1); mitogen-activated protein
kinase 8 (MAPK8); MyoD family inhibitor domain containing (MDFIC); midkine (neurite
growth-promoting factor 2) (MDK); opioid receptor, kappa 1(OPRK1); periostin
(POSTN); phosphopantothenoylcysteine decarboxylase (PPCDC); protein tyrosine
phosphatase, receptor type, F(PTPRF); solute carrier organic anion transporter family,
member 2A1(SLCO2A1); small VCP/p97-interacting protein (SVIP); transglutaminase 1
isoform (TGM1); thrombospondin, type I, domain containing 7A (THSD7A); winglesstype MMTV integration site family, member 5B (WNT5B); WW and C2 domain
containing 1 (WWC1); zinc finger homeobox 3 (ZFHX3) and zinc finger protein 655
(ZNF655). Several genes known to be dysregulated in ovarian adenocarcinoma were
also found in our differential list of genes; namely apolipoprotein E (APOE); ATPase,
aminophospholipid transporter, class I, type 8B, member 1 (ATP8B1); CXXC finger
protein 5 (CXXC5); fibroblast growth factor 18 (FGF18); low density lipoprotein receptorrelated protein 8 (LRP8); met proto-oncogene (hepatocyte growth factor receptor)
(MET); tissue inhibitor of metalloproteinases 3 (TIMP3) and vascular endothelial growth
factor A (VEGFA). Consistent with what we would expect to find, many differentially
expressed genes were implicated in cancer (Figure 3.7 and Table 3.4).
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3.3 DISCUSSION
Based on microarray findings, a 70-gene predictor for breast cancer was identified by
Van’t veer et al. that is now currently available commercially as MammaprintTM (van 't
Veer, Dai et al. 2002). Another test, Oncotype DX assay, utilizes expression analysis of
21 genes for risk stratification and prognosis of breast cancer patients (Ishibe, Schully et
al. 2011). Two long term large scale randomized trials (Trial Assigning Individualized
Options for Treatment [TAILO]Rx and Microarray In Node- Negative and 1 to 3 Positive
Lymph Node Disease May Avoid Chemotherapy [MINDACT]) are underway to
determine the clinical utility for Oncotype DX and MammaprintTM tools. With regard to
DCIS, a study by Adeyinka et al. identified 69 genes that were expressed at significantly
different levels between low and high-grade DCIS (Adeyinka, Emberley et al. 2002).
Another study compared 12,000 transcripts in a larger cohort of samples including ADH,
DCIS, and IDC and found gene expression profiles to be highly similar in DCIS and IDC,
but a signature of 85 genes separated DCIS and IDC (Ma, Salunga et al. 2003). A
diagnostic and prognostic application of microarrays in ovarian cancer has been
reported by Kim and colleagues (Kim, Skates et al. 2002). A previous microarray study
in ovarian cancer reported up regulation of osteopontin gene in cancer samples
compared to normal samples (Wong, Cheng et al. 2001). In the clinical study by Kim et
al., a similar up regulation in osteopontin protein concentrations was found in plasma
samples of ovarian cancer patients as reported in microarray findings by Wong et al.
This reflects the potential of microarrays in identifying biomarkers of disease, which
after proper validation may be used in the clinical setting.

43
In the present study, our aim was to gain an insight into transcriptional signatures of
various DCIS models using microarrays and to identify genes marking the transition
from non-tumorigenic mammary epithelial cells to premalignant lesions. Obtaining high
quality gene expression data from formalin fixed paraformaldehyde embedded (FFPE)
samples is quite challenging due to variation in fixation and extraction procedures, and
also the age of samples.

Here, we used an in vitro 3D overlay culture model to

circumvent the technical issues associated with microscopic clinical specimens. In the
first part of research, our major focus was to establish and standardize the protocols to
obtain high quality RNA samples from cell cultures grown in 3D rBM. We minimized
variability issues by adopting uniform procedures for cell culture conditions, RNA
extraction

and

subsequent

processing

of

samples.

The

RIN

values

and

electropherograms of all the samples reflect high quality RNA samples and their
suitability for microarray analysis.

The profile plot for gene expression in MCF10A

replicates and MCF10.DCIS replicates corroborates the quality and reproducibility of the
biological replicates.
The hierarchical clustering of samples indicates robustness of microarray data as the
three DCIS models cluster together and separate from normal MCF10A samples. We
have applied stringent criteria for identification of differentially expressed genes
common to the three DCIS models in comparison to MCF10A. The observation that
MCF10.DCIS has more genes common with MCF10A as compared to either SUM102
or SUM225 is consistent with the fact that MCF10.DCIS and MCF10A are isogenic.
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3.3.1 Down-regulation of matrix assembly genes
We observed more than tenfold down regulation in expression levels of various
genes involved in regulation of matrix assembly such as NID1 (Nidogen-1), DCN
(decorin), and POSTN (periostin). Nidogens provide structural stability to basement
membrane by connecting laminin and collagen IV networks. They interact with various
integrins and play an important role in cell adhesion.

Loss of nidogen expression

weakens the basement membrane and favors invasion. A study by Ulazzi and coworkers reported that loss of NID1 expression observed in colon and gastric tumors is
due to aberrant methylation in NID1 promoter (Ulazzi, Sabbioni et al. 2007). Nidogen-1
was also found to be significantly under-expressed in a gene expression analysis in
embryonic stem cell-cloned blastocysts implicating its aberrant expression in
developmental disorders in embryos (Jincho, Sotomaru et al. 2008).

Genome-wide

association study identified nidogen 1 (NID1) as a susceptibility locus to melanoma risk
(Nan, Xu et al. 2011).
Another down-regulated gene that we observed in our microarray analysis is
periostin.

It is a matricellular cell adhesion protein that interacts with multiple cell-

surface receptors like integrins. There have been conflicting reports on the role of
periostin in tumor development and progression. Kim et al. have suggested its role as a
suppressor of invasion and metastasis in the progression of bladder cancer (Kim,
Yoshioka et al. 2005). They observed down regulation of periostin expression in highgrade bladder tumors.

However, many studies report the role of periostin over-

expression in promoting tumor invasiveness. Over-expression of periostin has been
observed in various malignant tumors such as metastatic breast cancer (Contie,
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Voorzanger-Rousselot et al. 2011), metastatic ovarian cancer (Zhu, Fejzo et al. 2010)
and high-grade prostate cancer (Tischler, Fritzsche et al. 2010). In a recent study, Ben
et al. reported that periostin may be involved in the progression and invasion of
pancreatic cancer (Ben, Jin et al. 2011). We have observed marked down-regulation of
periostin expression in our premalignant DCIS models. This may be explained by the
fact that periostin up-regulation is related to the tumor aggressiveness in most cancers
and DCIS is a pre-invasive stage of breast cancer.
Decorin (DCN) modulates the activity of transforming growth factor β and plays an
important role in the process of tumor growth and progression. It acts as a tumor
suppressor gene and its de novo gene expression suppresses the malignant phenotype
of human colon cancer cells (Santra, Skorski et al. 1995). Down-regulation of decorin
expression leads to increased proliferation in intestinal epithelium and decorin over
expression in colorectal cancer cells inhibits cancer cell proliferation and migration (Bi,
Tong et al. 2008; Bi, Pohl et al. 2012). In an independent study by Mlakar et al., the
authors observed under-expression of DCN and another gene (SLC26A3) in colorectal
tumors (Mlakar, Berginc et al. 2009). In our study, we found down-regulation of DCN,
which may imply its contributory role in to the events driving the premalignant
progression in DCIS.

3.3.2 Signaling pathways and networks
One approach to interpret the microarray results is to analyze each gene separately,
and then draw conclusions at the pathway level by combining results on individual
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genes in the pathway. However, in view of the complexities of cancer, we know that
causative genes and proteins do not operate in isolation and it may be more relevant to
study their interactions (Barros and Offenbacher 2009). Hence, we employed a network
modeling approach, Ingenuity pathway analysis (IPA), and uploaded our microarray
data into IPA to define the molecular networks and pathways associated with our
differentially expressed genes.

The microarray analysis showed that a subset of

differentially expressed genes in DCIS is strongly linked to glutamate metabolism,
suggesting a possible molecular link between this pathway and premalignant breast
disease. Glutamate receptors mediate a diverse array of cellular signaling responses
and their over-expression has been observed in several malignancies. For example,
metabotropic glutamate receptor (Grm) has been reported to be over expressed in
invasive breast cancer (Speyer, Smith et al. 2012). Furthermore, Wei et al. did whole
exome sequencing of patient matched normal and melanoma samples and reported
that the ionotropic glutamate receptor gene, GRIN2A, was the most highly mutated of all
the genes. Using cell signaling pathway analysis, they identified glutamate signaling to
be the most significant pathway implicated in melanoma (Wei, Walia et al. 2011).
Another biological pathway associated with differentially expressed genes in our
dataset was integrin signaling. We observed more than 10-fold up-regulation of ITGB2
(also known as CD18 or Mac1) gene in all DCIS models. Inhibition of CD18 has been
shown to enhance tumor response to radiation therapy (Ahn, Tseng et al. 2010). The
authors showed that tumors were more sensitive to irradiation when grown
in CD18 hypomorphic mice. Further, when CD18 hypomorphism was partially rescued
by reconstitution with the wild-type bone marrow, the tumors recovered resistance to
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irradiation. We also observed down regulation of integrin alpha 9 (ITGA9) which has
previously been reported to be deregulated in non small cell lung cancer (Anedchenko,
Dmitriev et al. 2008) and premalignant cervical lesions

(Mitra, Mazumder Indra et al.

2010). The role of frequent alterations in ITGA9 and other genes (RBSP3 and hMLH1)
in early dysplastic lesions of head and neck has been characterized by Ghosh and coworkers (Ghosh, Ghosh et al. 2010).
Our pathway analysis of microarray data revealed activation of Retinoid X receptor
(RXR) pathway as one of the significant biological pathways in which differentially
expressed genes are involved. Retinoid X receptor (RXR) is a combinatorial partner for
about one third of the 48 human nuclear receptor superfamily members. It acts as a
master regulator of nuclear receptor signaling pathways involved in the control of cell
growth and differentiation (Tanaka and De Luca 2009). In a study using several breast
cancer cell lines, Bonofigolo and co-workers demonstrated that ligand activation of
peroxisome proliferator-activated receptor (PPAR) gamma and retinoid X receptor
(RXR) induces antiproliferative effects (Bonofiglio, Cione et al. 2009).
Many genes involved in lipid metabolism and fatty acid biosynthesis were found to be
altered in our premalignant DCIS samples.

We observed up-regulation of

sphingomyelin phosphodiesterase, acid-like 3B (SMPDL3B), stearoyl-CoA desaturase
(SCD), lipase member I (LIPI), low density lipoprotein receptor related protein 8 (LRP8),
acyl-CoA oxidase 1, palmitoyl (ACOX), insulin induced gene 1 (INSIG1) and downregulation of apolipoprotein E (APOE) and acetyl-CoA carboxylase beta (ACACB)
genes. These findings suggest that alteration in lipid metabolism may be a key driving
force in the early events of premalignant progression.

A recent comprehensive
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lipidomics study conducted in human breast cancer tissues by Hilvo and colleagues
provides further support to our observations (Hilvo, Denkert et al. 2011).

They

investigated the global lipid profiles of breast cancer tissues and found that the products
of de novo fatty acid synthesis were increased in tumors as compared to normal breast
tissues. These lipids were associated with cancer progression and their concentration
was highest in estrogen receptor-negative and grade 3 tumors. They observed high
expression of several lipid metabolism regulating genes such as ACACA (acetyl-CoA
carboxylase α), ELOVL1 (elongation of very long chain fatty acid-like 1), FASN (fatty
acid synthase), INSIG1 (insulin-induced gene 1), SCAP (sterol regulatory elementbinding protein cleavage-activating protein) and SCD (stearoyl-CoA desaturase) in their
study.
The

presence

of

genes

related

to

insulin-like

growth

factor

(IGF) signal

transduction pathway in our differential genes list emphasizes the importance of
targeting the IGF pathway in breast cancer. The prevailing view is that targeting the
IGF pathway in triple-negative breast cancers is not of any benefit as their growth is not
IGF-responsive. However, a recent report by Davison et al. shows that IGF stimulates
cell proliferation and promotes cell survival in triple-negative breast cancer cells
(Davison, de Blacquiere et al. 2011).

In MCF7 breast cancer cells, IGF-1 confers

increased invasive potential and induces activation of TGF-β1 leading to epithelial to
mesenchymal transition (Walsh and Damjanovski 2011). Over expression of insulin-like
growth factor 1 (IGF-1) and its receptor (IGF-1R) has also been reported in low-grade
serous ovarian carcinoma (King, Zu et al. 2011).

Studies of IGF-1R inhibitors are

currently ongoing in pancreatic, gastroesophageal, hepatocellular and colorectal
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cancers.

Clinical trials with IGF-1R inhibitors in patients with Ewing sarcoma have

shown significant anti-tumor activity (Golan and Javle 2011).
In summary, we have identified several important genes that are differentially
expressed in DCIS as compared to normal epithelium in this microarray study. Further
characterization of genes that show significant changes in expression in DCIS in
comparison to non-transformed MCF10A will provide important clues and directions for
our next in depth studies.

The present study also clarifies pathway networks that

function in premalignant lesions of DCIS.

The results demonstrate that glutamate

metabolism, IGF-1 signaling, integrin signaling and fatty acid metabolism are
significantly associated with the early neoplastic changes.

Further experimental

investigations are required to elucidate the consequences of these biological pathways
and their relevance in driving early premalignant changes in breast tissue. Those data
could provide biomarkers and could lead to the development of novel efficacious targets
to treat premalignant progression of breast cancer.
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Figure 3.1: Different morphologic characteristics of non-transformed mammary
epithelial cells and DCIS models grown in 3D rBM overlay culture. Differential
interference contrast (DIC) images of 12-day 3D rBM overlay cultures of MCF10A,
MCF10.DCIS, SUM102, and SUM225 cells. Scale bar, 200 µm.
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Figure 3.2a: Electrophoresis gel image of RNA samples extracted from biological
triplicates of MCF10A, MCF10.DCIS, SUM102 and SUM225 cultured in 3D. The
cells were grown in 3D overlay cultures in 171 media with mammary epithelial growth
supplements for 12 days. The purity and integrity of RNA samples was determined
using Agilent Bioanalyzer 2100 using the Eukaryote Total RNA Nano assay.
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Figure 3.2b: Electropherograms of RNA samples extracted from biological
triplicates of MCF10A, MCF10.DCIS, SUM102 and SUM225 cultured in 3D. The
purity and integrity of RNA samples is depicted by RIN values and was determined by
Agilent Bioanalyzer 2100.
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Figure 3.3a: Cluster dendrogram of microarray samples: Unsupervised hierarchical
clustering of 12 samples shows that the normal MCF10A and the three models of DCIS
have low correlation coefficient. In the dendrogram the length of the branches between
two elements reflect their degree of relatedness. The three DCIS cluster together and
separately from normal MCF10A. The biological replicates cluster together within each
sample subtype.
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Figure 3.3b Gene expression profiles by hierarchial clustering. Heatmap showing
expression profiles of MCF10A and MCF10.DCIS, SUM102 and SUM225 samples
using > 54000 probes. The green color represents relative gene over-expression while
the red color indicates relative gene under-expression.
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Figure 3.4: Profile plot of normalized gene expression in paired analyses of
MCF10.DCIS versus MCF10A. Each line represents an individual gene product, with
the values in MCF10A triplicates shown at left and those in MCF10.DCIS shown at right.
Red indicates transcripts that are decreased, yellow indicates that are unchanged and
blue indicates that are increased.
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Figure 3.5: Differentially expressed genes between MCF10A and the three DCIS
models. Venn diagram showing the overlap between the genes expressed by the
different models of DCIS: MCF10.DCIS, SUM102 and SUM225 as compared to the
MCF10A model of non-tumorigenic mammary epithelial cells.
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Figure 3.6: Significant canonical pathways associated with the differentially
expressed genes. Probe sets identified as differentially expressed in all models of
DCIS were uploaded into Ingenuity Pathway Analysis software. A Fisher's exact test
was used to test the statistical significance with a significance level of 0.05.
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Figure 3.7: Significant biological processes and pathways associated with the
differentially expressed genes. Probe sets identified as differentially expressed in all
models of DCIS were uploaded into Ingenuity Pathway Analysis software. A Fisher's
exact test was used to test the statistical significance with a significance level of 0.05.
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Table 3.1: The genes with the largest fold change in expression identified in the
list of those differentially expressed by microarray. The values represented in the
second column are the fold changes in expression (with a p-value of < 0.05) in all
models of DCIS over those expressed in normal MCF10A model. The red arrows
indicate up regulation in expression and green arrows indicate down regulation in
expression.
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Table 3.2: List of molecules in glutamate metabolism pathway. Arrows pointing
up (in red) and down (in green) indicate up and down regulation of genes respectively.
The values are the fold change values with a p-value of < 0.05 in all models of DCIS as
compared to normal MCF10A.
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ID

Molecules in Network

1

C1q, C1S, caspase 3/7, COL6A1, collagen, CSN,
DCN, DUSP1, EHF, Fibrinogen, FOXP1, GAS6,
GFPT2, HLA-DQB1(includes others),HOX A2, Hsp
27, IgG , IL1, IL33, IL1RAP, Immunoglobulin, ITPKB,
MAP3K5*, MAPK8IP3, MERTK, NFκB(complex),
PDPN, RRBP1*, Sapk, SH3RF1*, TFAP2C, TLE6,
TNFRSF12A, TRAF4

2

ACACB,
ADAMTS5,
AMPK,
BICD1,
BTG3,
CLEC11A, DYNC1I1, Erk1/2, Fcer1, Fgf, FGF1,FGF
18, H1F0, HDL, HTRA1, IRS1, Mek, MET, NTN4,
p70S6k, PLC gamma, POSTN, PP2A, RAB4A,
RAB4AB* RHEB,PRKAG2, Rsk, SCD*, SOCS6*,
TGFB2, TIMP3*,UNC5, UNC5B, UNC5C

3

A4GALT, ABLIM2, AP1S2, Caspase, CD70,
CHEMOKINE, COTL1, CROT, Cyclin E, F Actin,
FBXW7, Gpcr, HIP1, HNRNPC, Hsp90, Ige,
IL12(complex), IL6R, Interferon alpha, Jnk, KIF23,
LRRK2, MHC ClassII(complex), Mmp, NEDD4, NOV,
PYHIN1, RAPGEF6, SCN8A, SHROOM3, SNX33,
SREK1, STAT, TJP3, Trypsin

4

14-3-3, Alp, Alpha Actinin, BRCA2, CES2*, CXCR4,
DBNDD1, FKHR, Foxo, FOXO1*, FOFO3, GRB10,
ID1, ID3, IER3, IGF1R, Laminin, MAP2K1/2, MEGF10,
NEXN, P85(pik3r), PCSK5, PDGF BB, PDLIM1,
PI3K(complex), POU2AF1, PTK6, PXR ligand-PXRRetinoic acid_RXRα, Rar, SLCO1A2, Smad,
STAT5A/B, TM4SF1*, VEGFA*

5

26sProteasome, Akt, Ap1, APOE*, ARHGEF9, BGN,
CDKN2C, CDON, CLMN, COL2A1, Collagen type I,
Collagen(s), Creb, CyclinA, Estrogen receptor,
FKBP1B, GMNN, GPSM2, HOXA7*, Iκb, INSIG1*,
LDL, LRP8*, NEDD9, P38 MAPK, PDCD4*, Proinflammatory Cytokine , Rb,Rxr, SLC12A2, Tgf beta,
TLL1, TP73, Ubiquitin, Vegf

6

ACOT2, ACOX1, AQP8, BHMT, C14orf147, CHDH*,
COPS8, COPS7A, COPS7B, CYP3A43, CYP4F2,

Focus
Molecules

Top Functions

25

Hematological
disease,
infection
mechanism

24

cellular
development,
embryonic
development,
gastrointestinal
disease

21

cell cycle,
cellular
assembly and
organization

20

cellular growth
proliferation, cell
death, skeletal
and muscular
development
and function

26

18

cardiovascular
disease,
organismal
injury and
abnormalities,
cancer

25

17

lipid
metabolism,

Score

43

40

33

30
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CYP7B1, CYP8B1, ETNIκ2, GSTM4, HNF4A,
HSPH1*, KLF15 MGST3, MREG, NAT8, PLD2,
PPP1R11, PPP1R3C, PPP2R5B, RORA, SLC25A24,
SLC35D1, SLCO1A2, SRSF11, SSFA2, SULT1A1,
TMEM43, TRIP11, ZBTB45

7

ACER3, ATP2A1, BDNF, Ca2+, CDCA2, CDK1,
CHAF1B, DCN*, DEFB103A/DEFB103B, EFCAB4B,
EGR2, ERK1/2 FZD2, GABRA5, GCGR, GLP2R,
IDI1*, IL4, KCNA3, KISS1R, LAT2, LTB4R2, MATK,
MMP12, NRG1, NXPH4, OBFC2A, ORAI1, POSTN,
SLAIN1, SOX 13, TAC1, TGM1, TMED5, ZNF33B

8

ATP8B1, ATP8B2, ATP9A, BAMBI, C1S, CD2AP,
COL6A1, DOCK8*, FGA, FOXC1, FZD2, KRT17, LSR,
MG2+-ATPase, OSM, PDLIM5, PDPN, PKIG, PSG1,
RAB25, RAC1, SERPINB1, SFN, SLC4A11, SNAI1,
SYNJ2, TAL 1, TGFB1, TNS4, VPS37B, WISP1,
YWHAB, ZNF266, ZNF395

9

ADAM12, ANKS1B, beta-estradiol, BICD1, CDK18,
CLDN7, CMTM6, CXCR7, CYP4B1, DLG4, FZD1,
FZD2, FZD7, GPM6A, GRB2, ID4, KCNJ10, KRT7,
LEPROT, LPHN1, LRRC1, NOVA1, OPRK1, OPRM1,
PLEKHA6, PTGER2, PTPN13, PTPRN, PXDN,
PYG01, SH2D4A, SLC22A5, SNTB2, SPARCL1,
SSTR2

10

ADAMTS5, AP1S2, ASAP2, butyric acid, CCND1,
CCPG1, COL4A1, COL4A2, DBI, ESR1, ESYT2,
FAM102A, FBLN1, FST, GAD2, HBE1, HTT,
MAN1A1, MAPK8, MDFIC, MDK, OPRK1, POSTN,
PPCDC, PTPRF, SERPING1, SLCO2A1, SVIP*,
TGM1, THSD7A, tretinoin, WNT5B, WWC1, ZFHX3,
ZNF655

11

ADH1A, ADH1B, ADH1C, ALDH16A1, ALDH5A1,
C/ebp, C1R, C8orf4, CD4, Ck2, DUSP1, EBAG9,
FAM69B, GLCCI1, GLUL, HAS2, Histone h4,
HOXA7*, INSM2, MED13, MED31, NOL3, NR3C1*,
OASL, ONECUT1, PPID, PRR15L, pyridoxal

small molecule
biochemistry,
endocrine
system
development
function

23

23

21

20

19

16

cell death,
hypersensitivity
response

16

cellular growth
and
proliferation,
cellular
development,
cellular
movement

15

reproductive
system disease,
biliary
hyperplasia

15

cellular growth
and
proliferation,
cellular
development,
reproductive
system
development
and function

14

small molecule
biochemistry,
infectious
diseases,
cellular function
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phosphate, RBMS2, RNA polymerase I, SDPR,
SLC25A2, SUB1, WDR12
12

13

APBB2, ASPM, ATF4, CLCN3, CLCN5, Cofilin,
COL6A1, Collagen type IV, Cytokeratin, DCN*, EGFR,
FBLN2, FBN1, FNDC3B, FZD2, GLI1, KRT7, LAMC2,
MTHFD2*, PARP, PARP3, PARP4, PARP8, PARP9,
PCDH18, POSTN, RIN2, SERPINE2, SESN3,
SLC23A2, TGFB1, TGFBR3, Tpsab1, WISP1, ZNF226

ADAP1, ARHGAP29*, CAP2*, EHD4, EIF4EBP2,
ERK, ERO1L, Focal adhesion kinase, FSH, G protein
alphai, G-protein beta,
GLUD1, GPR56*, Gsk3,
GULP1*, hCG, Histone h3, Insulin, ITGB2, JAM3, Lh,
Mapk, Nfat (gamily), PDXK, PGGT1B, Pka, Pkc(s),
RAB3IP, Rac, Ras, Ras homolog, RG53, Sfk, Shc,
TCR

and
maintenance

19

18

14

cellular
movement,
connective
tissue disorders,
genetic
disorders

15

cell –to-cell
signaling and
interaction,
cellular
movement,
hematopoiesis

Table 3.3: Signaling pathway networks involving differentially expressed genes.
The IPA analysis of differentially expressed genes revealed several statistically
significant pathway networks. Each network includes genes from microarray analysis
as focus molecules and indicated in bold. The statistical score of > 3 was considered
significant (p value < 0.01).
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Diseases and Disorders

p-value

No. of molecules

Cancer

2.25E-07 - 1.54E-02

106

Genetic Disorder

2.06E-06 - 1.71E-02

178

Neurological Disease

1.94E-05 - 1.71E-02

112

Cardiovascular Disease

4.56E-05 - 1.71E-02

75

Reproductive System Disease

9.43E-05 - 1.41E-02

55

Molecular and Cellular Functions

p-value

No. of molecules

Cellular Growth and Proliferation

3.74E-07 - 1.66E-02

79

Cell-To-Cell Signaling and Interaction

6.36E-06 - 1.71E-02

34

Cellular Assembly and Organization

9.93E-05 - 1.71E-02

27

Lipid Metabolism

1.09E-04 - 1.71E-02

28

Small Molecule Biochemistry

1.09E-04 - 1.71E-02

40

Physiological System Development
and Function

p-value

No. of molecules

Tissue Development

6.36E-06 – 1.57E-02

45

Connective Tissue Development

1.18E-05 - 1.71E-02

27

Skeletal and Muscular System
Development and Function

1.18E-05 - 1.71E-02

26

Tumor Morphology

8.45E-05 – 1.03E-02

19

Organ Development

1.62E-04 – 1.56E-02

32

Table 3.4: Biological functions associated with the differentially expressed genes.
The values in the second column represent the statistical significance score (p value) of
each biological function. The number of molecules represents the number of
differentially expressed genes in the microarray dataset that are involved with a
particular biological function.
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CHAPTER 4

DEEP SEQUENCING BASED EXPRESSION ANALYSES VALIDATE MICROARRAY
FINDINGS AND REVEAL NOVEL POTENTIAL TARGETS IN THE PREMALIGNANT
PROGRESSION OF BREAST CANCER

4.1 BACKGROUND AND RATIONALE
Microarrays have been the technology of choice for most gene expression studies.
However, the enormous amount of expression data generated by microarrays requires
further validation.

The two most common approaches employed by researchers to

validate the microarray results are: quantitative real time polymerase chain reaction
(qRT-PCR) and repeating the experiment with another, different microarray platform.
Here, we have used an advanced approach by employing deep sequencing or next
generation sequencing (NGS) technologies along with qRT-PCR for validating the
microarray results. The major reason for choosing NGS over a different microarray
platform is because of the clear advantages that these sequencing technologies have
over microarrays. The deep sequencing technology does not rely on prior sequence
information as required for probes used for microarrays. Identification and quantification
of gene expression at the whole genome level without a priori sequence knowledge
provides higher confidence in discovering novel targets and network pathways.

Also,

as NGS uses sequencing instead of hybridization, there are no cross-hybridization or
background noise issues. The NGS data are obtained as countable digital signals that
can be recorded, quantified, annotated and re-annotated as per the current genome
databases. We have used two NGS tools namely Digital Gene Sequencing (DGE) and
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a more comprehensive technique, RNA-Sequencing (RNA-Seq) in order to confirm our
array data.
Ultra high throughput sequencing by DGE allows for detection of differentially
expressed transcripts especially low abundance transcripts. It also enables detection of
rare transcripts, differential polyadenylation and antisense transcription. DGE uses 3’
end tag for transcriptional reads, however, RNA-Seq covers the full length mRNA and
provides comprehensive transcriptional profiling.

RNA-Seq is particularly useful in

revealing transcriptional boundaries, novel, rare transcripts and alternative splice
variants.

Additionally, RNA-Seq provides an insight into post transcriptional

modifications and re-arrangement events as well. For example, reads that align to
exon–exon junctions when mapped to the reference genome indicate splicing events.
Also, reads containing poly (A) tracts that are not encoded in the reference genome are
indicative of poly-adenylation. When the reads contain sequence polymorphisms in
comparison to the reference genome this may illustrate potential RNA editing events
(Figure 4.1).
Currently, there are three NGS platforms available commercially: FLX pyro
sequencing system (454 Life Sciences); Illumina Genome Analyzer (developed by
Solexa); and AB SOLiD system (Life Technologies). The underlying principle in all the
NGS technologies is same; however, the approaches used to produce sequence reads
may differ. In general, a population of RNA molecules is first converted into a cDNA
library and then after fragmentation, adaptors are ligated to cDNA. Each molecule is
then sequenced base-by-base in a high throughput manner. The sequencing may be
done from a single end or both ends (paired-end) and data are obtained as short
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sequences or reads. The reads are then aligned to a reference genome as well as the
corresponding genes or assembled de novo to create a transcription map. We used
Illumina Genome analyzer for RNA-seq and used single end sequencing (76 cycles) for
generating sequence reads in the present study.

As described in details below,

employing deep sequencing not only validated our microarray results but also enhanced
the depth of gene expression data with identification of novel transcripts and common
regulatory frameworks. Furthermore, we validated the microarray expression findings
and deep sequencing data with another orthogonal tool, i.e., qRT-PCR. Hence, we
employed an array of diverse technologies to consolidate and compliment the data
findings from microarray with the aim of elucidating potential gene targets for further
characterization.

4.2 RESULTS

4.2.1 Digital Gene Expression (DGE) validates microarray results and identifies
novel transcripts
In collaboration with Krawetz lab at the Mott Center at Wayne State University, we
first confirmed the results from our microarray analysis with Illumina G2A digital gene
sequencing. As DGE is very sensitive in detection of low abundance transcripts and of
small changes in gene expression, we expected that it would not only validate but also
enrich the expression profiling data from microarrays. We determined digital gene
expression of the same RNA samples extracted from MCF10A and the three DCIS
models as those used for microarray analysis.

The reads expressed from all the
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samples were mapped to 33,000 genes and then the gene candidates were annotated
in NCBI map viewer. We used reads on the sense strand < 500 bp from the 3’ end to
infer expression and compared all the reads against MCF10A to detect fold changes in
expression. We observed that 154 genes of the 290 genes in the Affymetrix list of
differentially abundant genes generated sufficient signal in the DGE data to assess fold
change in expression. In the un-normalized read data, 123 (80%) of the fold change
values were in the same direction in the DGE data as in the Affymetrix data. We
therefore obtained strong qualitative concordance between the Affymetrix microarray
and Illumina DGE results (Figure 4.2). We found 79 genes consistently differentially
expressed between MCF10A model of non-tumorogenic breast epithelial cells and the
three models of DCIS: MCF10.DCIS, SUM102 and SUM225 (Table 4.1).

The fold

change in expression levels in DCIS relative to MCF10A of some selected genes
common to both Affymetrix and DGE analyses are depicted in Table 4.2. Ontology
analysis of these 79 differentially expressed genes suggested few common groups, all
of which were generally weak with respect to multiple hypothesis testing. The major
functions associated with these genes were tissue/organ development and fibronectin
pathways. Studies are currently ongoing in our lab to investigate the role of fibronectin
in progression of DCIS to invasive breast cancer.
Further analysis of digital gene expression data revealed a broad range of antisense
transcripts and transcripts that are transcribed outside of standard (NCBI 36.3) gene
models.

Reads from one of the genes, vesicle-associated membrane protein 2

(VAMP2) or synaptobrevin 2, are shown mapped to the University of California Santa
Cruz (UCSC) browser to illustrate antisense transcription and transcription far from 3'-
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untranslated regions (UTRs), both of which may be linked to silencing transcripts
(Figure 4.3). Analysis of DGE results also revealed truncated transcripts for the gene
endoplasmic oxidoreductin-1-like (ERO1L). The data showing truncated transcripts for
ERO1L is illustrated in Figure 4.4.
4.2.2 mRNA-Seq reveals unique differentially expressed transcripts and validates
both microarray and DGE findings
At the next level of validation, we employed a step forward approach using whole
transcriptome sequencing or mRNA-Seq for expression profiling of samples from the
two biological replicates of each of the DCIS models (MCF10.DCIS, SUM102 and
SUM225) and the MCF10A model of non-tumorigenic mammary epithelial cells. The
reads obtained from each sample were grouped to generate clusters and mapped back
to the genome as well as the corresponding genes. Using Novoalign software, greater
than 80% alignment to the reference genome was observed for all the samples. The
number of reads and clusters for each of the RNA-Seq samples is shown in Table 4.3.
Based on a log2 fold change > 2 and adjusted p-value < 0.001, we identified 1,103
genes in MCF10.DCIS, 2,388 genes in SUM102 and 3,036 genes in SUM225 as
significantly differentially expressed in comparison to MCF10A.

Volcano plots from

each individual model are depicted in Figure 4.5. The number of significant differentially
expressed transcripts that were common to all the three DCIS models in comparison to
non-tumorigenic MCF10A were 295 (Figure 4.6, Appendix).
Among the 295 differentially expressed, 63 genes were significantly up-regulated in
all three models, 156 genes were down-regulated, and 76 genes showed differential
expression but their pattern of up and down regulation was not consistent.
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We also performed hierarchical clustering analysis to assess the relatedness of the
different DCIS models (MCF10.DCIS, SUM102 and SUM225) and non-transformed
mammary epithelial cell model (MCF10A). Unsupervised clustering based on the total
number of sequence reads shows that the two biological replicates have a very high
correlation coefficient and that there is also a good correlation between the expression
profile of the isogenic MCF10A and MCF10.DCIS models (Figure 4.7A).

When

clustering is based on differentially expressed transcripts (Figure 4.7B), the
MCF10.DCIS samples are much less correlated with MCF10A samples as compared to
when total transcripts are considered. The DCIS models derived from two individual
patients (SUM102 and SUM225) are more highly correlated when clustering is based on
differentially expressed transcripts (Figure 4.7B) as opposed to the total number of
reads (Figure 4.7A).

4.2.2.1 Validation of microarray and DGE results by mRNA-Sequencing
We compared our microarray and DGE findings with RNA-Sequencing results to see
whether there is any correlation among the results obtained with different platforms. We
observed an overlap in microarray and RNA-Seq results with 238 significantly
differentially expressed genes observed in common by both the technologies (Figure
4.8). We then compared the DGE analysis with the RNA-Seq data and found that
almost all the DGE data completely confirm with the RNA-Seq data. The consistency
analysis between the DGE results and mRNA-Seq results is reported in Table 4.4.

4.2.2.2 Detection of novel differentially expressed transcripts by mRNA-Seq
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The genes detected by deep sequencing as most significantly differentially overexpressed in DCIS in comparison to normal MCF10A include anterior gradient homolog
2 (AGR2); grainyhead like (Drosophila) (GRHL2); apolipoprotein D (APOD); chemokine
(C-C motif) ligand 20 (CCL20); cation transport regulator homolog 1 (E. coli)(CHAC1);
claudin 4 (CLDN4); lipocalin 2 (LCN2); lipase member H (LIPH); fucosyltransferase 3
(FUT3) and cAMP responsive element binding protein 5 (CREB5). The genes which
were found be significantly down-regulated include alcohol dehydrogenase 1B (class I),
(ADH1B); RNA, Ro-associated Y5 (RNY5); transforming growth factor, beta-induced
(TGFBI); podoplanin (PDPN); tolloid-like 1 (TLL1); dermatopontin (DPT); cell adhesion
molecule 3 (CADM3); aspartoacylase (ASPA); Duffy blood group, chemokine receptor
(DARC) and nidogen 1 (NID1).

Some of these genes were also identified by the

microarray and DGE analyses whereas several other genes are unique to RNA-Seq
analysis only.

The genes identified by RNA-Seq as significantly differentially over

expressed or under expressed in all three models of DCIS are depicted with their fold
change values in Table 4.5.

4.2.2.3 Biological functions and pathways related to differentially expressed
transcripts
The transciptomic data obtained from mRNA-Seq analysis of all DCIS and normal
mammary epithelial cell models were analyzed with IPA software to define which wellcharacterized cell-signaling and metabolic pathways could be the most relevant during
the premalignant progression.

Network pathway analysis showed three statistically

significant cell signaling and metabolic pathway networks (Table 4.6). Each network
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includes the differentially expressed genes as focus molecules along with other related
genes from the IPA database. The top network relates to connective tissue disorders,
genetic disorders, dermatological diseases and conditions and includes 74 focus
molecules or genes with a statistical significance score of 131. The genes playing a key
role in this network include but are not limited to A4GALT, ANKRD2, APOE, CCL20,
CD70, CLDN4, CLDN9, COL17A1, DCN, ELF3, FGFR3, FOXO1, GPR56, LAMB1,
MMP28, MYL9, NFATC4, NID1, PDGFB, POSTN, RAP1GAP and SERPINF1. The
second network functions in cellular development, lipid metabolism and molecular
transport and includes 43 significantly differentially expressed genes.

Some of the

focus molecules playing a key role in this network include AGR2, ANKRD13B, APOD,
ARL14, BSPRY, CADM3, CHAC1, CREB5, DQX1, DPT, FAM65B, GRHL2, JAM3,
KRT7, LIPH, PDPN, RAB25 and SEPT6. The third most significant network pertains to
lipid metabolism, small molecule biochemistry, organismal injury and abnormalities.
This network involves 26 focus molecules from the differentially expressed list of genes.
Some of the genes involved in this network are ABTB2, ADH1B, ALDH5A1, ASPA,
CALML3, CHST2, ETNK2, FUT3, GGT6, HIP1, KCNB1, LRRK2, MMP28, PLCH2,
RNY5 and SEMA5B.
IPA also identified major functions and canonical pathways associated with the
differentially expressed genes.

The canonical pathways include atherosclerosis

signaling, leukocyte extravasation signaling, tight junction signaling, PTEN signaling and
glycosphingolipid biosynthesis (Figure 4.9). Significant molecular and cellular functions
in which a high number of differentially expressed genes are implicated correspond to
cell-cell signaling and interaction; cellular movement; cellular organization and
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assembly; cellular function, maintenance and development (Figure 4.10 and Table 4.7).
Some of the important genes regulating the processes of cell-cell signaling and
interactions identified in our data analysis are PDPN, APOE, SCD, CADM3, SFTPD,
TWIST1, CCL20, SDC3, WISP2, NID1, TNFRSF12A, ELF3, EDN2, LAMB1, POSTN,
HOXA7, CDH13, FUT3, DARC, TIMP3, TGFBI, DCN, BGN, COL2A1, COL17A1,
SERPINF1, INPP5D, PDGFB, GPR56, RAP1GAP, CSF1, JAM3 and ZEB2.
Functional annotation of the differentially expressed genes revealed cancer as the
most significant disease followed in order of significance by inflammatory disease,
connective tissue disorders, genetic disorders and dermatological diseases (Table 4.7).
The analysis emphasized the functions of cell-cell signaling and interaction, cellular
movement, and cellular organization and assembly and the disease of cancer as
significantly associated with the DCIS gene signature. Indeed, many of the significantly
differentially expressed genes have previously been implicated in cancers other than
breast (Table 4.8).
WebGestalt2 (Duncan) and Genomatix GePS were also employed to identify
biological processes related to the common significant transcripts from the RNA-Seq
data.

These two other tools independently mine the relationships and thus yield their

own curated data sets. The results showed that a large number of the differentially
expressed genes are involved in cell adhesion, cell proliferation, response to chemical
and organic stimuli, lipid metabolic processes, organ development and morphogenesis.
The corresponding biological processes are summarized in Figure 4.11 with the number
of associated genes and their statistical significance.

Their associated molecular

functions include protein binding, receptor binding, fibroblast growth factor receptor
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activity, enzyme regulatory activity, type II transforming growth factor beta (TGFβ)
receptor binding, platelet derived growth factor binding and glycosaminoglycan binding.
Classification of the differentially expressed genes from the DCIS models by cellular
component revealed a striking focus of gene expression changes in the plasma
membrane and extracellular region (Figure 4.12). Overlaying GePS also revealed 11
pathways to be most relevant to the differentially expressed genes in DCIS (Table 4.9).
These pathways were dominated by signaling events mediated through integrins,
patched homolog1, fibroblast growth factor, TGFβ, hepatocyte growth factor, signal
transducer and activator of transcription (STAT) and RhoA.

4.2.2.4 Common framework analysis in the promoters of differentially expressed
up-regulated genes

We further explored the mRNA-Seq results to gain an insight into common
frameworks in the promoter regions of differentially expressed genes. The genes were
classified into up-regulated or down-regulated. The up-regulated genes (63) were then
sub- grouped by biological functions for common framework mining.

Using the

Genomatix Gene2Promotor program, the promoter regions of the up-regulated genes
were identified and then screened for common transcription factor binding site (TFBS)
modules with Genomatix program tools. From a total of 82,703 promoter sequences in
the entire human genome, 244 promoter loci were found to be associated with the 63
up-regulated genes.

Enrichment analysis of common frameworks showed that

V$STAT-V$PERO-V$RXRF-V$NFKB is highly enriched (254.2 fold) in 4 genes in the
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entire human genome and 3 of those genes are present in our RNA-Seq data. These
genes are ELF3, CCL20 and NFATC4 and the gene not detected by RNA-Seq but
present in the genome with this framework is IL-9R. A schematic illustration for this
common framework binding to the promoters of three genes is represented in Figure
4.13. Also, significant enrichment (336.36 fold) was observed for common framework
consisting of five TFBS elements (RXRF-ZF02-ZF02-PLAG-HDBP) which is present in
promoter regions of RAP1GAP, SPRY4 and PDGFB genes in the entire human genome
and all three of these genes are present in our dataset.

The results of common

framework mining in the promoters of differentially expressed up regulated genes are
summarized in Table 4.10.

4.2.3 Quantitative real time polymerase chain reaction (qRT-PCR) supports the
validity of different platforms used for detection of differentially expressed
transcripts
Having validated the array results with deep sequencing technologies, we employed
another independent measure for quantification of transcript abundance namely qRTPCR to confirm our findings. In addition to the microarray data, we also validated the
expression of select genes identified as differentially expressed by mRNA-Seq analysis
as well.
For qRT-PCR validation, we selected candidate genes based on significant fold
changes in expression observed in both microarray and RNA-Seq analyses and based
on their association with the identified canonical and biological pathways. We chose a
total of nineteen genes that were either identified by both microarray and mRNA-Seq
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analysis or that were uniquely identified by either analysis.

The venn diagram

summarizing the genes selected from microarray and RNA sequencing data for qRTPCR validation is shown in Figure 4.14. Since adequate quantification of target gene
expression relies upon appropriate use of internal reference genes, in all our
experiments we normalized the expression of our target genes to three housekeeping
genes (HPRT, ACTB and GUSB). The qRT-PCR results were in concordance with
results from the array and sequencing approaches for fifteen of the nineteen genes and
the results for four of the genes (RHOB, FOXO3, GLUL and MET) are partially
inconsistent among different platforms.

The overall correlation among the different

platforms was good with correlation coefficient between microarrays and qRT-PCR
being 0.82 and that between RNA-seq and qRT-PCR being 0.86. We observed that the
qRT-PCR results agreed more closely with the RNA-Seq results than with the
microarray (Table 4.11).

The expression fold change values of selected genes in

MCF10.DCIS, SUM102 and SUM225 over MCF10A as detected by microarray, RNASeq and qRT-PCR are compared in Table 4.12.

4.3 DISCUSSION
In the present chapter, our major objective was to validate the findings from the
microarray study by using diverse platforms. We first used digital gene expression to
obtain the transciptomic profiles of all DCIS and MCF10A samples. The DGE analysis
very well confirmed the microarray results as indicated by the strong qualitative
concordance in the data obtained by the two platforms. In addition, DGE also unraveled
many novel differentially expressed transcripts that were not identified by microarray.
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Two interesting observations in the transcriptome sequencing data command particular
attention. Firstly, the presence of antisense transcripts for the gene VAMP2 indicates
an additional level of transcriptional regulation. VAMP2 belongs to the family of vesicle
associated membrane proteins and a recent evidence points to its role in trafficking of
alpha5beta1 integrin to the plasma membrane, which is crucial in cell adhesion,
migration and survival (Hasan and Hu 2010). The antisense transcripts observed for
VAMP2 may be responsible for degradation of the corresponding sense transcripts and
transcriptional silencing of VAMP2.

Also the antisense transcripts link neighboring

genes into chains of linked transcriptional units thereby regulating expression
(Katayama, Tomaru et al. 2005). Another notable observation in the sequencing data
was the presence of truncated transcripts for the gene ERO-1L. This gene is known to
be induced by hypoxia and plays a key role in VEGF secretion (May, Itin et al. 2005).
The pathophysiological role of truncated form of ERO1L in breast cancer progression
needs to be elucidated.
In the DGE data, we obtained fewer reads in MCF10A samples as compared to
signals from the three DCIS models. Instead of repeating the experimental run for DGE
(for 3’UTR regions), we extended our approach by sequencing the full length mRNA
using mRNA-Seq in order to confirm the findings from digital gene expression as well as
from microarray. The global transcriptome profiling by RNA-Seq corroborated both the
microarray and DGE data as well as revealed many novel differentially expressed
transcripts in DCIS.

The hierarchical clustering of RNA-Seq samples indicates the

robustness of the data and the reproducibility of the biological replicates.

The

observation that MCF10.DCIS has more genes in common with MCF10A than with
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either SUM102 or SUM225 is consistent with the fact that MCF10.DCIS and MCF10A
are isogenic.

4.3.1 Differentially Expressed Genes in Models of DCIS
The implication of the differentially expressed genes being involved in the processes
of cell-cell adhesion, cell proliferation and movement signify the importance of
deregulation of these processes very early in the course of premalignant progression.
Interestingly, the down-regulated differentially expressed genes with largest fold change
in expression pertain to the functions of cell adhesion and include CADM3 (cell
adhesion

molecule

3),

DPT

(Dermatopontin),

NID1

(nidogen1)

and

TGFBI

(Transforming growth factor beta induced). The latter is consistent with the previous
observation that the level of TGFBI decreases in progression from benign breast tissues
to DCIS and IDC (Calaf, Echiburu-Chau et al. 2008).

TGFBI activates adhesion-

associated signaling and decreases the motility in breast cancer cells both in vitro and
in vivo. It also reduces the activation of matrix metalloproteinases (MMPs) 2 and 9,
which are responsible for the degradation of extracellular matrix (Wen, Partridge et al.
2011).
In contrast to decreased TGFBI that has previously been associated with DCIS,
decreased CADM3, DPT, and NID1 have not previously been linked to breast cancer.
CADM3 also known as nectin like protein 1 (Necl1) is a cell-cell adhesion molecule and
has been reported to suppress tumorigenicity in colon cancer cells (Raveh, Gavert et al.
2009). Loss of its expression has been detected in various gliomas (Gao, Chen et al.
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2009). DPT is involved in cell adhesion and promotes ECM assembly. Downregulation
of DPT has been previously observed in oral squamous cell carcinoma and is
associated with lymph node metastasis (Yamatoji, Kasamatsu et al. 2011). Decreased
expression of DPT in hepatocellular carcinoma has also been reported (Li, Feng et al.
2009). We also observed greater than tenfold down regulation in expression levels of
NID1 (Nidogen-1). Loss of NID1 expression has been observed in colon and gastric
tumors due to aberrant methylation of NID1 promoter (Ulazzi, Sabbioni et al. 2007), and
NID1 has been identified as a susceptibility locus for melanoma in a genome-wide
association study (Nan, Xu et al. 2011).
Some of the significantly over-expressed genes found in DCIS included AGR2
(anterior gradient 2), CLDN4 (claudin 4) and LCN2 (lipocalin 2). The presence of AGR2
in primary breast tumors is correlated with poor survival (Barraclough, Platt-Higgins et
al. 2009), and elevated expression of AGR2 is related to treatment failure with
tamoxifen (Hrstka, Nenutil et al. 2010). High levels of CLDN4 have been reported in
basal-like breast cancers (Kulka, Szasz et al. 2009).

In gastric carcinoma, high levels

of CLDN4 have been found to be significantly associated with MMP-9 expression, which
in turn can degrade type IV collagen of ECM and facilitate cancer cell invasion (Lee, Wu
et al. 2008). In comparison, increased LCN2 promotes breast cancer progression and
metastasis by facilitating epithelial-to-mesenchymal transition (Yang, Bielenberg et al.
2009).

The increased expression of LCN2 in our data may be explained by its

regulation to be under the control of NFKB signaling. Up-regulation of LCN2 has been
observed in an NF-KB dependent manner in prostate cancer cells under the conditions
of ER stress (Mahadevan, Rodvold et al. 2011).
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Several findings from our sequencing study are in agreement with results from other
gene expression profiling studies in DCIS. Down regulation of DST and HTRA1 has
been associated with progression to invasive breast cancer (Lee, Stewart et al. 2012;
Wang, Eckert et al. 2012) and was found in our data-set. Similarly, upregulation of
GJB2 expression, which is involved in local invasion of breast ductal carcinoma
(Castellana, Escuin et al. 2012), was also found.

We observed differential gene

expression of several collagens (1A1, 2A1, L4A6, 7A1,8A1 and 17A1) in DCIS models,
but not the related family members (e.g.,11A1 and 5A2) that have previously been
reported to be involved in progression of DCIS to IDC (Vargas, Reed et al. 2012).
Similar to the findings of comparative microarray analyses of MCF10A and
MCF10.DCIS trancriptomes (Rhee, Park et al. 2008), we found up regulation of ABTB2,
CX3CL1, DHRS9, GRHL2, HNMT, KRT6B, KRT7, LCN2, MYEOV, PLEKHF1, SEMA4A
and TNFRSF12A; down regulation of APOE, C1R, COL4A6, D4S234E, KRT14 and
PCDH7; and differential expression of several members of various gene families like
ALDH, CAPN, CCDC, CHST, ITGB, SLC and TMEM.

4.3.2. Signaling pathways and networks
The integration of differentially expressed genes identified by mRNA-Seq into known
biological pathways greatly facilitated our comprehension of the complex gene
expression data. Involvement of the common differentially expressed genes in various
signaling pathways such as FGF signaling, TGFβ receptor binding, integrin signaling
and PDGF binding highlights the cross-talk between these pathways and reiterates the
complexity of cancer progression. Thus while the focus on individual genes that were
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significantly down regulated or over expressed identified many candidates that had not
previously been considered in the context of breast cancer, the majority of the networks
and pathways identified from the results were concordant with those that might have
been predicted.
The role of FGF signaling has been well characterized in mammary gland
development and also in progression of breast cancer. Elevated expression of several
FGFRs, including FGFR1, FGFR2, FGFR4, and FGFR10 has been previously reported
in several studies in breast cancer.

A recent study (Sharpe, Pearson et al. 2011)

reported that FGFR signaling mainly via FGFR2 promotes the growth of triple- negative
breast cancer. However, the role of FGFR signaling in the context of DCIS has not
been studied in depth. Further characterization of the differentially expressed genes
involved in FGFR signaling pathway will provide further insights into its role in
premalignant progression of breast cancer.
TGF-β plays an important tumor suppressor role in the early phase by preventing
epithelial cell proliferation or by inducing apoptosis. The precise role of TGF-β depends
upon the balance between its canonical and non canonical signaling pathways (Parvani,
Taylor et al. 2011). Enrichment of differentially expressed genes in the TGFB signaling
indicates that this pathway is active during the premalignant stages as well.

A

significant association between TGFβ and E-cadherin, β-catenin and c-met has been
observed in DCIS cases progressing to invasive ductal cancer (Logullo, Nonogaki et al.
2010).
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Another biological pathway associated with differentially expressed genes in our
dataset was integrin signaling. We observed up-regulation of ITGB2 (also known as
CD18 or Mac1) gene in all DCIS models.

Inhibition of CD18 has been shown to

enhance tumor response to radiation therapy (Ahn, Tseng et al. 2010). The authors
showed

that

tumors

were

more

sensitive

to

irradiation

when

grown

in CD18 hypomorphic mice. Further, when CD18 hypomorphism was partially rescued
by reconstitution with the wild-type bone marrow, the tumors recovered resistance to
irradiation (Ahn, Tseng et al. 2010). We also observed down regulation of integrin alpha
9 (ITGA9), which has previously been reported to be deregulated in several
malignancies such as non small cell lung cancer (Anedchenko, Dmitriev et al. 2008).
The role of frequent alterations in ITGA9 and other genes (RBSP3 and hMLH1) in early
dysplastic lesions of head and neck has been characterized by Ghosh and co-workers
(Ghosh, Ghosh et al. 2010).
Collectively, we can infer that these different signaling pathways act in concert to
drive the premalignant changes in the breast.

The overall pattern of changes

emphasizes modifications in the interaction of the cells with their environment, with
major changes in the expression of gene products that localize to the plasma
membrane and the extracellular region, and alterations in cellular adhesion, motility and
signaling. Delineation of the genetic hierarchy and interactions of the various genes
involved in these pathways may further elucidate their mechanism in governing the
premalignant progression.
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4.3.3. Common frameworks as regulatory modules
In further analysis of our RNA-Seq data, we interrogated the promoters of
differentially over-expressed genes in DCIS in order to decipher the regulatory
connections existing among these genes.

A particular physiological process or a

cellular signal can induce the expression of a distinct set of genes mediated by binding
of transcription factors to their corresponding binding sites.

These well defined

regulatory modules present in the promoter regions can influence the expression of
genes within the same class or may regulate the expression of different unrelated
genes.

The common promoter structures may explain the functional regulation of

different co-expressed genes that have no detectable sequence similarity (Werner
2001). Hence, we performed in-silico analysis to explore the transcriptional regulatory
networks that are responsible for the gene expression profiles we observed in our RNASeq study. We found that a common framework comprising of four transcription factors
elements namely STAT (signal transducer and activator of transcription), PERO
(Peroxisome proliferator activated receptor), RXRF (RXR heterodimer binding sites) and
NFKB (nuclear factor k B) is highly enriched. This framework may be of particular
significance and provides a possible explanation of the co-expression of three different
genes (ELF3, CCL20 and NFATC4).

The identification of coexistence of RXRF and

PERO is important as RXR physically interacts with PERO or peroxisome proliferatoractivated receptor (PPAR-α) in regulating lipid metabolism and inflammation.

This

finding is in line with our previous pathway analysis of differentially expressed genes
that indicated activation of Retinoid X receptor (RXR) pathway and lipid metabolism to
be one of the most significant biological pathways.
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ELF3 or E74-like factor 3 (ets domain transcription factor, epithelial-specific) is
located at chromosome 1q32 in a region, which is known to be amplified in almost 50%
of early breast cancers.

Protein encoded by ELF3 transactivates Ets-responsive

promoter elements including that are present in the Her-2/neu oncogene (Chang, Scott
et al. 1997). Our findings confirm the previous reports that over-expression of ELF3
occurs in DCIS samples (Chang, Scott et al. 1997). ELF3 was shown to differentially
activate several malignancy-associated gene promoters and regulate cellular survival of
human mammary cells (Eckel, Tentler et al. 2003).
A second gene that shares the regulatory motifs with ELF3 for binding of the above
mentioned four transcription factors is CCL20. It is interesting to note that CCL20 is
also among the top 10 significantly differentially expressed genes in our RNA-Seq data.
It belongs to a large family of chemotactic cytokines that participate in directing
inflammatory cell migration and in modulating angiogenesis (Kleeff, Kusama et al.
1999). CCL20 is also known as Macrophage Proinflammatory Human Chemokine3alpha (Mip-3alpha/LARC/Exodus) and its expression has been reported to be under
the direct control of TNF-dependent NF-kappaB activation (Sugita, Kohno et al. 2002).
Significant up-regulation of CCL20 and its receptor CCR6 was found in pancreatic
adenocarcinoma and higher expression was associated with the advanced stage of the
disease (Rubie, Frick et al. 2010). In a mouse model of colorectal cancer, Liu et al.
observed that tumor-associated macrophages recruit CCR6+ regulatory T cells and
promote colorectal cancer by enhancing CCL20 production (Liu, Zhang et al. 2011). In
a recent study, the prognostic value of the chemokines CCL19, CCL20 and CCL21 and
their receptors CCR6 and CCR7 was assessed in non metastatic breast cancer. The
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study found that CCR6 (receptor for CCL20), CCL19 and CCR7 expression correlated
with histologic features of aggressive disease (Cassier, Treilleux et al. 2011). In an
another study, expression and secretion of chemokine CCL20 was observed to be
dramatically increased in breast cancer cells in the presence of adipocyte culture
medium, which in turn stimulated metastasis of breast cancer cells. Interestingly, the
authors observed that an NF-kappaB blocker completely inhibited adipocyte culture
medium-induced CCL20 expression (Kim, Baek et al. 2009). This finding underscores
our observation of predicted transcriptional regulation of CCL20 gene by NFKB.
The third gene regulated by the common binding of the four transcription factors is
NFATC4. The product of this gene is a member of the nuclear factors of activated T
cells and plays an important role in the inducible expression of cytokine genes in T cells,
especially in the induction of the IL-2 and IL-4. NFATC4 has been reported to regulate
peripheral vascular development during embryogenesis. It is expressed in perivascular
tissues that influence the development of endothelial cells and vascular smooth muscle
cells. Interaction of NFATC4 with ERalpha and ERbeta has been observed both in vitro
and in mammalian cells. NFATC4 also acts as negative regulator of adiponectin gene
expression in obesity and type 2 diabetes (Kim, Kong et al. 2006). In non small cell
lung cancer, the expression of NFATC4 was significantly associated with the expression
of COX-2 (Zhao, Chen et al. 2010).

COX-2 over expression has been previously

reported in DCIS and is associated with poor prognosis (Sakorafas, Farley et al. 2008).
A recent study reported that NFATC4 signaling reduces motility of breast cancer cells
through inhibition of Lipocalin 2 (LCN2) gene expression (Fougere, Gaudineau et al.
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2010). In our study, we observed LCN2 as one of the ten most significantly differentially
over-expressed genes.
The other common framework that was found to be most highly enriched in our
comparative promoter analysis comprised of five elements (RXRF-ZF02-ZF02-PLAGHDBP) and likely regulates the genes RAP1GAP, SPRY4 and PDGFB. The protein
encoded by the gene RAP1GAP is a Rap1 GTPase-activating protein that inhibits the
RAS superfamily protein Rap1 by facilitating hydrolysis of GTP to GDP. Downregulation of Rap1Gap has been reported to promote cell proliferation and invasion in
thyroid cancer (Zuo, Gandhi et al. 2010). The down-regulation of Rap1GAP impairs
cell-matrix adhesion, but its role in the regulation of cell-cell adhesion is complex and
not completely understood (Vuchak, Tsygankova et al. 2011).

The observed over-

expression of RAP1GAP in our data is intriguing and requires further investigations to
characterize the significance of its over-expression in DCIS. Studies have been initiated
in our lab to further explore the role of Rap1Gap in premalignant progression of breast
cancer.
Another gene co-regulated by the common framework is SPRY4 (sprouty homolog
4), which is an inhibitor of the receptor-transduced mitogen-activated protein kinase
(MAPK) signaling pathway.

Sprouty-4 has been shown to inhibit transformed cell

growth, migration and invasion, and epithelial-mesenchymal transition in non small cell
lung cancer cells (Tennis, Van Scoyk et al. 2010).

Additionally, SPRY4 has been

shown to regulate angiogenesis by inhibiting vascular endothelial cell growth factorinduced extracellular signaling-regulated kinase (ERK) activation. The expression of
SPRY4 was found to be increased under the conditions of hypoxia (Haigl, Mayer et al.
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2010). In a recently published report, over expression of SPRY4 and its long noncoding
RNA SPRY4-IT1 was detected in melanoma.

The elevated expression levels of

SPRY4-IT increased cell growth and decreased apoptosis in melanoma cells (Khaitan,
Dinger et al. 2011). The functional relevance of increased expression of SPRY4 that we
observed in the premalignant DCIS samples needs to be further investigated.
The third co-regulated gene with RAP1GAP and SPRY4 is PDGFB. The product of
this gene belongs to the family of platelet derived growth factors that are mitogenic
factors for the cells of mesenchymal origin. In breast cancer, high PDGFB expression
in stroma has been reported to be significantly associated with high histopathological
grade, estrogen receptor negativity and high HER2 expression (Paulsson, Sjoblom et al.
2009). In gastric carcinoma, secretion of PDGFB and expression of its receptor PDGFRβ by tumor-associated stromal cells are involved in mediating lymphatic metastasis
(Kodama, Kitadai et al. 2010).
To conclude, here we have used a systematic in silico approach to analyze the genes
with similar expression patterns by exploring their promoter sequences.

We have

identified concerted modulation of several genes controlled by binding of transcription
factors into well conserved common regulatory motifs.

Our data reveal complex

transcriptional networks in DCIS that may be driving the premalignant progression.
Further experimental studies will be required to validate the putative crosstalk between
the co-expressed genes that we have observed in our data.
Lastly, as the final step of orthogonal validation of our microarray and deep
sequencing data, we used quantitative real time PCR. Good correlation between the
qRT-PCR, microarray and sequencing results indicates the strength of these

88
independent techniques in quantifying the gene expression levels and cross platform
reproducibility of results.
In summary, in the present study we were able to confirm the microarray results
using deep sequencing techniques as well as quantitative real time PCR. The present
study also expands the scope of our knowledge on molecular mechanisms, signaling
pathways and regulatory networks operative in the premalignant progression of breast
cancer.

Further experimental studies on the novel candidates and the functional

pathways unraveled in this study may help discover potential biomarkers and develop
efficacious therapeutic agents.
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Figure
4.1:
Identification
of
post-transcriptional
modifications
and
rearrangements by RNA-sequencing. A) Reads spanning exon–exon junctions
indicate splicing events. B) reads containing poly (A) tracts that are not encoded in the
reference genome signify poly-adenylation events. C) reads containing sequence
polymorphisms as compared to the reference genome indicate editing sites. (Adapted
from Marguaret and Bahler, Cell Mol Life Sci., 2010)
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Figure 4.2: Qualitative concordance between data obtained from Affymetrix
microarray and Illumina digital gene expression. In the un-normalized read data,
123 (80%) of the fold change values were in the same direction in the DGE data as in
the Affymetrix data. Each dot on the graph represents a single differentially expressed
gene.
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Figure 4.3: DGE signal reads for VAMP2 showing antisense transcription. Reads
mapped to UCSC genome browser showing MCF10A & SUM102 sense and antisense
reads around the gene VAMP2. Lower signal with more antisense (silencing) reads are
evident in SUM102 relative to MCF10A.
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Figure 4.4: Read profiles exhibiting truncated transcripts in the gene ERO1L.
Reads mapped to UCSC genome browser showing truncated transcripts in SUM102
relative to MCF10A.
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A)

B)

C)

Figure 4.5: Volcano plots depicting differential expression of genes in various
DCIS models versus MCF10A. X-axes represent log2 (fold change) and Y-axes
denote adjusted p-values for each plot. Each black dot represents a single gene. A)
MCF10.DCIS vs MCF10A; B) SUM102 vs MCF10A; C) SUM225 vs MCF10A. Note that
the ranges of the x-axes are variable and the spread of the data for the comparison of
MCF10.DCIS vs MCF10A is the narrowest.
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Figure 4.6: Venn diagram of differential expression results showing the overlap
between the genes expressed by different models of DCIS in comparison to
MCF10A. There are a total of 295 genes that are differentially expressed (with a pvalue < 0.001 and log2 fold change ≥ 2) in common to the three DCIS models:
MCF10.DCIS, SUM102 and SUM225 in comparison to MCF10A.
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Figure 4.7: Cluster dendrogram of mRNA-Seq samples. Unsupervised hierarchical
clustering of MCF10A and three DCIS models from the eight RNA-Seq samples
showing the biological replicates in all groups have high correlation coefficient (A)
Clustering based on total transcript profile (B) Cluster dendrogram based on
differentially expressed genes.
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Figure 4.8: Venn diagram illustrating the overlap between significant genes from
RNA-Seq (right) and microarray (left). The overlap between the two circles represents
the common differentially expressed genes detected by both techniques.
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Figure 4.9: Significant canonical pathways associated with the differentially
expressed genes. The list of genes identified as differentially expressed in all models
of DCIS were uploaded into Ingenuity Pathway Analysis software. A Fisher's exact test
was used to test the statistical significance with a significance level of 0.05.
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Figure 4.10: Significant biological processes and pathways associated with the
differentially expressed genes. The list of differentially expressed genes in DCIS as
compared to MCF10A identified by mRNA-Seq analysis was uploaded into Ingenuity
Pathway Analysis software. A Fisher's exact test was used to test the statistical
significance with a significance level of 0.05.
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Figure 4.11: Significant biological processes associated with the differentially
expressed genes as identified by Genomatix. The differentially expressed genes in
all models of DCIS in comparison to MCF10A were analyzed by WebGestalt2 tool. A
Fisher's exact test was used to determine statistical significance with a significance level
of 0.05. The p-values and the number of genes associated with a particular function or
process are indicated in bold in the respective boxes.
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Figure 4.12: Cellular components related to significantly differentially expressed
genes. The differentially expressed genes in all models of DCIS in comparison to
MCF10A were analyzed by WebGestalt2 tool. The p-values and the number of
differentially expressed genes associated with a particular cellular function or process
are indicated in bold in the respective boxes.
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Figure 4.13: Schematic display of genes sharing common regulatory motifs.
Promoters for three genes (ELF3, NFATC4 and CCL20) contain the common framework
comprising of four elements V$STAT-V$PERO-V$RXRF V$NFKB. The ‘V$' prefixes to
the individual matrices are representative of the Vertebrate MatInspector matrix library.
STAT (signal transducer and activator of transcription); PERO (Peroxisome proliferator
activated receptor); RXRF (RXR heterodimer binding sites) and NFKB (nuclear factor k
B).
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Figure 4.14: Venn diagram showing the genes chosen for validation by qRT-PCR.
The genes were selected from overlap of microarray and mRNA-Seq results and also
those detected either by microarray or sequencing only.
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AHNAK2
ALDH5A1
C1orf62
CCNO
COL17A1
CYP4B1
ELF3
ETNK2
GPSM2
HTRA1
LOC100130394
LOC401206
LOC642587
MIRN205
MORF4L1
NEBL
PDLIM1
PLEKHA6
RGS2
RPL41P2
SCRN1
SESN1
SPRY4
STC2
TCEB2
TGFBI
PIP4K2C

HMG17L1
KRCC1
KRT15
ALAS1
TACSTD1
VAMP2
ITGB4
SECTM1
NSF
DQX1
TOX2
IL20RB
RNF126
HMHA1
ANKRD28
DPP9
FKBP1B
LOC100129867
ATAD4
XPC
RPS4L2
MREG
PSMA7
ID1
ALS2CL
MXD4
HSPH1

FOXO1
RPS3
NLGN2
SLC7A2
PHLDA1
MGC4655
ARF5
GRINA
MOBKL2B
ZNF395
CDH3
TTC9C
DUSP6
DFNB31
PGAM4
KRT6B
LOC440335
GPR56
ANXA1
SFRP1
MRPL51
B4GALNT4
TRAPPC1
LRFN4
EML3

Table 4.1: Differentially expressed genes identified by digital gene expression. A
total of 79 genes consistently differentially expressed between MCF10A model of
normal human breast epithelium and the three models of DCIS: MCF10.DCIS, SUM102
and SUM225.
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Table 4.2: Comparison of differential expression levels of selected genes by
Affymetrix and DGE analysis. The fold change in expression levels in DCIS relative
to MCF10A are depicted.
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Sample

No. of reads

No. of clusters

Clusters/percentage

MCF10A-2

10,465,483

97,237

8,952,978 (84.6%)

MCF10A-3

9,158,711

80,872

7,920,391 (86.5%)

DCIS-2

9,576,827

86,842

7,904,905 (82.5%)

DCIS-3

7,566,009

82,166

6,390,646 (84.5%)

SUM102-1

10,052,168

87,122

8,531,282 (84.9%)

SUM102-2

6,968,895

74,876

5,706,991 (81.9%)

SUM225-1

9,906,081

92,650

8,404,428 (84.8%)

SUM225-2

8,337,795

84,549

6,866,336 (82.4%)

Table 4.3: Generation of clusters from the reads obtained by deep sequencing of
different samples. Biological duplicates of MCF10A, MCF10.DCIS, SUM102 and
SUM225 samples were run in the Solexa flowcell. No. of reads indicates the total
number of short reads that uniquely aligned to reference genome. The reads from each
sample were grouped into clusters using two parameters: 1. window size 100bp; 2.
number of reads per cluster > 9. No. of clusters indicates those generated from the
reads based on Poisson distribution. The reads that did not group in any cluster were
considered as background and discarded. Clusters/percentage indicates reads in
clusters compared with the total number of reads.
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Samples

RNA-Sequencing

Digital gene expression

Common

No. of
clusters

No. of mapped
genes

No. of
clusters

No. of mapped
genes

MCF10A

80,872

11,991

206

171

153

MCF10.DCIS

86,842

11,625

630

586

537

SUM102

87,122

11,859

926

844

781

SUM225

92,650

11,857

1,664

1,435

1,288

Table 4.4: Consistency analysis between DGE and RNA-Seq data. The clusters of
reads generated from MCF10A, MCF10.DCIS, SUM102 and SUM225 samples and
corresponding number of mapped genes were compared for both the runs. Most genes
are consistent between RNA-Seq and DGE. The genes detected only in DGE
correspond to the clusters with less number of reads.
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Top Molecules
Log Ratio up-regulated

Log Ratio down-regulated

Molecules

Exp Value

Molecules

Exp Value

AGR2

↑ 5.011

ADH1B

↓ -10

GRHL2

↑ 4.435

NID1

↓ -8.728

APOD

↑ 4.239

DARC

↓ -8.382

CCL20

↑ 4.219

ASPA

↓ -8.323

CHAC1

↑ 4.161

CADM3

↓ -8.173

CLDN4

↑ 3.97

DPT

↓ -8.058

LCN2

↑ 3.87

TLL1

↓ -7.994

LIPH

↑ 3.855

PDPN

↓ -7.757

FUT3

↑ 3.804

TGFBI

↓ -7.586

CREB5

↑ 3.714

RNY5

↓ -7.581

Table 4.5: Genes with the largest fold change in expression identified in the list of
those differentially expressed. The significantly differentially over-expressed in DCIS
in comparison to normal MCF10A include anterior gradient homolog 2 (AGR2),
grainyhead like (Drosophila) (GRHL2), apolipoprotein D (APOD), chemokine (C-C motif)
ligand 20 (CCL20), cation transport regulator homolog 1 (E. coli) (CHAC1), claudin 4
(CLDN4), lipocalin 2 (LCN2), lipase member H (LIPH), fucosyltransferase 3 (FUT3) and
cAMP responsive element binding protein 5 (CREB5). The genes which were found be
significantly down-regulated include alcohol dehydrogenase 1B (class I), (ADH1B),
RNA, Ro-associated Y5 (RNY5), transforming growth factor, beta-induced (TGFBI),
podoplanin (PDPN), tolloid-like 1 (TLL1), dermatopontin (DPT), cell adhesion molecule
3 (CADM3), aspartoacylase (ASPA), Duffy blood group, chemokine receptor (DARC)
and nidogen 1 (NID1). The red arrows indicate up regulation in expression and green
arrows indicate down regulation in expression.
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ID

1

2

Molecules in Network
26s
Proteasome,A4GALT,Akt,Alp,ANKRD2,Ap1,APOE,BEX2,BG
N,C1q,C1R,CCL20,CD7,CD70,CDH13,CHEMOKINE,CLDN4,
CLDN9,cldn,COL17A1,COL1A1,COL21A1,COL22A1,COL28A
1,COL2A1,COL4A6,COL7A1,collagen,Collagen type
I,Collagen type IV,Collagen(s),CPE,CSF1,Cyclin
A,DARC,DCN,DST,EDN2,ELF3,ERK,ERK1/2,FGFR3,FKBP1
B,FOXO1,FSH,FZD2,GLI3,Gpcr,GPR56,GPR61,GPR84,GPR
113,GPR114,GPR144,GPR162,GPR174,GPR180,GPR89A/G
PR89B,GPR89C,Growth hormone,HIST2H2BE,Histone
h3,Histone h4,HOXA7,ID3,Ifn
gamma,Ige,IgG1,IgG,IGH@,Igm,IL1,INPP5D,Insulin,Integrin,I
nterferonalpha,Jnk,LAMB1,Laminin,LBH,LCN2,LDL,Lh,LMTK
3,MAPK13,Mapk,MMP28,Mmp,MT1E,MYL9,NFAT
(complex),Nfat (family),NFATC4,NFkB (complex),NID1,P38
MAPK,p85 (pik3r),PCDH7,Pdgf (complex),PDGF
BB,PDGFB,PI3K
(complex),Pkc(s),POSTN,PPARGC1B,PROCR,Rac,Rap1,RA
P1GAP,Ras,RIN1,RIN2,S100P,S1PR4,SCD,SECTM1,SERPI
NF1,SFTPD,Smad,SPRY4,SPSB1,TAAR8,Tgf
beta,TGFBI,TGFBR3,TIMP3,TJP3,TLL1,Tnf
receptor,TNFRSF12A,TNIK,TP73,TWIST1,UCN2,Vegf,VN1R
2,VN1R3,WISP2,ZBTB16ZEB2
ACSL4,ACSM3,ADAMDEC1,ADCYAP1,AGR2,AMACR,ANKR
D13B,ANP32E,APOD,arachidonic
acid,ARL14,ART3,B3GALNT1,BCAS4,betaestradiol,BSPRY,C9orf3,CADM1,CADM3,CCDC64B,CDK18,
CHAC1,CKMT1A/CKMT1B,CLCN2,CLEC2B,Clec2d (includes
others),CNN2,CORO6,CPXM1,CREB5,DLEU2,DLK2,DPT,DQ
X1,E2F1,Egfbp2,EGR2,ELOVL2,EPGN,ERBB2,FAM105B,FA
M110B,FAM129A,FAM50A,FAM65B,FBXO27,FOS,FRRS1,F
XYD5,G6pd2,GINS1,GLRA1,GLUD2,Gm10077,Gm10155,GR
HL2,heparin,HIST1H2AG (includes
others),HNMT,HTRA1,ICA1,IL6,IL29,INMT,JAM3,KDELR3,KI
AA0802,KLK11,KRT7,KRT13,KRT14,KRT81,L-alphalysophosphatidylcholine,
stearoyl,LEPROT,LIPH,LOC729505,LRRN3,LTBP3,MAP4,MA
PK6,MARK4,MED31,MGMT,MIA2,MLXIP,MSGN1,MYC,OMG
,PAQR7,PARD3,PCDHGC3,PDE7A,PDPN,PGLYRP1,PHGD
H,PLA2G2E,PLA2G2F,PLA2G4F,PLSCR1,PMPCB,PPT2,pro
gesterone,PRR15L,PRSS22,RAB10,RAB25,RFX2,RPL17,Rpl
9 (includes
others),RPLP1,RPS18,SATB1,SBNO2,SCRN1,SDC3,SEMA4
A,SEPT6,SLC13A3,SLC14A1,SLC39A14,SLC7A2,SOD2,SOL
H,SPAG4,SPEG,SPRR3,SQRDL,TDRD6,TERT,TGFB1,Timd
2,TMEM2,TMEM126A,TOX2,TRIM14,UST,YWHAZ,YY2,ZFP

Score

131

65

Focus
Molecules

Top Functions

74

Connective
Tissue
Disorders,
Genetic
Disorder,
Dermatological
Diseases and
Conditions

43

Cellular
Development,
Lipid
Metabolism,
Molecular
Transport

109
161,ZNF22

3

AATK,ABCB9,ABTB2,ACY1,ACY3,ADCK3,ADH6,ADH1B,AL
DH16A1,ALDH1L1,ALDH5A1,ALDH8A1,ANKRD49,APP,AQP
9,AS3MT,ASPA,BCL2L14,BPI,C21orf33,C7orf10,C8orf4,CAL
ML3,CALML4,Casein,CCDC76,CD300C,CDCA7L,CES2,CHS
T2,CHST4,CIDEC,COX11,CSRNP1,CTNNBL1,CWC15,CYP2
6B1,CYP4F3,D4S234E,DDX10,DDX18,DEFA4,DHRS3,DHR
S4,DLEU1,ECD,ECE2,ECI2,EIF4EBP2,ELMOD3,EPB41L4B,
ETNK2,EWSR1,FAM86C,FARSB,FASTKD2,FETUB,FEZF2,F
LRT3,FUT3,FUT4,FZD3,GGT6,GPX2,GRHL1,HGD,HIP1,HM
GN4,HNF4A,HS3ST1,HS6ST1,HSD17B11,IFT122,KCNB1,K
CNQ5,KIF3C,KLF15,LAD1,LGALS12,LRRC8C,LRRK2,MAP7,
MGST2,MMP28,MRPS18B,MSLN,MTF2,NBPF3,NDST1,NDU
FB1,NDUFV1,NLN,NR3C1,NR4A2,OAS3,OASL,OSCAR,OTU
D6B,PAFAH2,PARP4,PHB2,PLCH2,PLEKHF1,PWP1,RABG
GTB,RASL11B,RNY5,RTP3,SAMHD1,SEMA3C,SEMA5B,SE
PX1,SERPINB8,SLC25A20,SLC38A1,SLC5A3,STARD10,ST
T3A,SULT1C2,SUPT4H1,TMEM176B,TNF,TNFRSF21,TPCN
1,TPP2,tretinoin,TRIM15,TRIM35,TROVE2,TSPAN14,VMP1,
WDR37,WNT10A,WTAP,ZBTB11,ZDHHC6,ZNF133,ZNF146,
ZNF318

32

26

Lipid
Metabolism,
Small Molecule
Biochemistry,
Organismal
Injury and
Abnormalities

Table 4.6: Signaling pathway networks involving differentially expressed genes.
Ingenuity Pathway Analysis (IPA) of differentially expressed genes revealed several
statistically significant pathway networks. Each network contains focus molecules that
are obtained from RNA-Seq analysis and are indicated in bold. The other genes in the
network are derived from IPA database. The statistical significance score and top
functions associated with the molecules in network are also indicated in the table.
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p value

No. of
molecules

1.96E-09 - 1.08E-02

35

1.97E-07 - 1.08E-02

43

Cellular Assembly and
Organization

4.44E-06 - 1.11E-02

22

Cellular Function and Maintenance

4.44E-06 - 8.94E-03

11

Cellular Development

1.04E-05 - 1.11E-02

53

Diseases and Disorders

p value

No. of
molecules

Cancer

4.23E-09 - 1.07E-02

71

Inflammatory Disease

7.96E-07 - 9.89E-03

60

Connective Tissue Disorders

1.91E-06 - 8.94E-03

42

Genetic Disorder

3.40E-06 - 1.11E-02

100

Dermatological Diseases and
Conditions

4.96E-06 - 8.94E-03

31

Molecular and Cellular
Functions
Cell-To-Cell Signaling and
Interaction
Cellular Movement

Table 4.7: The molecular and cellular functions and diseases and disorders
associated with the differentially expressed genes derived from RNA-Seq data
analysis. The values in the second column represent the statistical significance score
(p value). The number of differentially expressed genes in the dataset are indicated in
the third column.
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Functions
Annotation

pValue

carcinoma

5.06E06

malignant
tumor

1.93E05

digestive organ
tumor

2.57E05

genital tumor
oral cancer
breast cancer
head and neck
tumor
prostate cancer
prostatic
carcinoma
uterine tumor
benign tumor
pancreatic
tumor
colorectal
cancer
metastasis of
lung

2.77E04
3.40E04

Molecules

No. of
Molecules

ADH1B, AGR2, ALDH5A1, APOD, APOE, BEX2, BGN, C1R,
CD70, CDH13, COL1A1, COL7A1, CSF1, FGFR3, GPR56,
HIP1, KRT14, KRT7, LCN2, MAPK13, MSLN, MT1E, MYL9,
PDPN, POSTN, RAP1GAP, SCD, SERPINF1, TIMP3, TLL1,
TNFRSF12A, TP73, TWIST1
ADH1B, AGR2, ALDH5A1, APOD, APOE, BEX2, BGN, C1R,
CD70, CDH13, COL1A1, COL7A1, CSF1, DCN, FGFR3,
FOXO1, GPR56, HIP1, IGH@, KRT14, KRT7, LCN2,
MAPK13, MSLN, MT1E, MYL9, PDPN, POSTN, RAP1GAP,
SCD, SERPINF1, TIMP3, TLL1, TNFRSF12A, TP73, TWIST1
ADH1B, APOE, BGN, COL1A1, CSF1, FGFR3, KRT14, KRT7,
LCN2, MAPK13, MSLN, PDPN, POSTN, RAP1GAP, SCD,
TIMP3, TP73, TWIST1
APOD, APOE, C1R, CDH13, COL7A1, CSF1, FGFR3, GPR56,
HIP1, KRT7, LCN2, MYL9, PDPN, TIMP3, TP73
BGN, COL1A1, KRT14, MAPK13, PDPN, S100P

AGR2, APOE, BEX2, CD70, CDH13, CLDN4, COL1A1, CSF1,
5.23EETNK2, FGFR3, FOXO1, HIST2H2BE, KRT14, LCN2, MT1E,
04
PDGFB, PDPN, SERPINF1, TLL1, TP73, TSPAN15
5.51E- ALDH5A1, BGN, FGFR3, KRT14, LAMB1, MAPK13, PDGFB,
04
PDPN, POSTN, RAP1GAP, TP73, TWIST1
5.58E- AGR2, ALDH5A1, APOD, C1R, CDH13, COL1A1, COL7A1,
04
CSF1, FGFR3, GPR56, HIP1, KRT7, MYL9, TIMP3, TLL1
7.39E- APOD, C1R, CDH13, COL7A1, CSF1, GPR56, HIP1, KRT7,
04
MYL9, TIMP3
7.93E- ADH1B, CDH13, CSF1, DPT, DST, FGFR3, HNMT, SPSB1,
04
TIMP3, TP73
ADH1B, DARC, DCN, DPT, DST, FGFR3, HNMT, LCN2,
8.06EMAPK13, SCD, SEMA5B, SPSB1, TGFBR3, TNFRSF12A,
04
WISP2, ZEB2
9.05E- BGN, FGFR3, KRT7, LCN2, MAPK13, MSLN, TWIST1
04
C1R, CLDN4, COL2A1, FGFR3, FUT3, HSD17B11, HTRA1,
1.15ELIPH, MT1E, PDPN, RAP1GAP, SECTM1, SLC2A14,
03
TGFBR3, TIMP3, TJP3, TNIK, TWIST1, WISP2
2.15E- CSF1, LCN2
03

Table 4.8: Significant differentially expressed genes involved in various types of
cancers. The number of focus genes and the p-values are indicated in the table.
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36

18
15
6
21
12
15
10
10
16
7
19
2
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Pathways

P value

Integrin signaling pathway

5.99e-03

Patched homolog 1 (drosophila)

4.54E-04

Fibroblast growth factor

5.41E-04

TGF beta

5.43E-04

Phosphatidylinositol

7.21E-04

Mothers against dpp homolog

1.68E-03

Rhoa ras homolog

2.80E-03

Indian hedgehog v akt murine thymoma viral
oncogene homolog 1

3.10E-03

V akt murine thymoma viral oncogene homolog 1

5.55E-03

Hepatocyte growth factor receptor

5.79E-03

Signal transducer and activator of transcription

8.94E-03

Table 4.9: Network pathway analysis of differentially expressed genes by
Genomatix. The genes identified as differentially expressed in all models of DCIS were
analyzed by Genomatix software. A Fisher's exact test was used to test the statistical
significance with a significance level of 0.05.
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Biological
Process

Regulation of
biological
processes

Communication

Regulation of
metabolic process

Defense
Response

Common Framework

No. of
frameworks
in 244
promoters

No. of
frameworks
in human
promoters

Enrichment

KLFS-EGRF-SP1F-CTCF

5

266

6.32

SP1F-ZF02-EGRF

11

2545

1.45

RXRF-ZF02-ZF02-PLAGHDBP

3

3

336.36

CTCF-EGRF-SP1F-KLFS

3

48

21.02

CTCF-ZF02-SP1F-KLFS

3

51

19.79

CFCF-EGRF-SP1F

20

5131

1.31

V$EBOX-V$NFKB-V$STAF

3

32

31.8

V$HNF1-V$SORY-V$HAND

3

134

7.6

V$LEFF-V$ZF02-V$GCMF

3

15

67.8

V$STAT-V$PERO-V$RXRF
V$NFKB

3

4

254.2

Table 4.10: Common framework mining in the promoters of differentially upregulated genes. Clustering by biological processes of differentially over expressed
genes in the DCIS models for promoter analysis. High enrichment for the common
frameworks V$STAT-V$PERO-V$RXRF V$NFKB and RXRF-ZF02-ZF02-PLAG-HDBP
is highlighted in red.
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RNA-Seq

qRT-PCR

Gene
Symbol

DCIS

SUM102

SUM225

DCIS

SUM102

SUM225

CASP2

-0.79

-0.57

-0.52

-3.09

-2.79

-3.80

DUSP5

1.38

2.49

3.57

-1.58

2.80

1.88

GRB7

0.59

2.34

7.64

1.42

11.19

126.47

PAK1

1.08

1.61

1.16

1.43

4.83

1.60

GPT2

-0.82

0.71

4.47

-2.16

2.38

48.84

Table 4.11: Comparison of the fold changes in gene expression of various genes
detected by RNA-Seq and qRT-PCR. The values represent the fold changes in
MCF10.DCIS, SUM102 and SUM225 compared to expression in MCF10A. The values
in the table are Log2 (Fold Change), positive value indicates up-regulated, negative
value indicates down-regulated.
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Microarray

RNA-Seq

qRT-PCR

Gene Symbol DCIS SUM102 SUM225 DCIS SUM102 SUM225 DCIS SUM102 SUM225
TIMP3

-4.56

-3.46

-5.05

-5.09

-3.81

-5.38

-9.24

-3.57

-103.54

GFPT1

1.64

2.57

3.57

0.50

1.15

2.70

3.074

5.063

13.833

RAB25

6.16

5.62

5.58

2.48

2.07

1.99

S100P

4.31

5.08

4.63

2.14

3.91

2.89

7.03

47.10

13.91

IRS1

-3.14

-2.44

-3.38

-3.38

-1.80

-2.97

-3.90

-1.39

-4.32

GLUL

-1.65

-3.18

-1.20

-3.79

-4.95

-2.40

3.78

1.31

4.25

KLK5

6.74

4.11

4.21

2.48

0.01

0.12

MET

-1.99

-0.88

-1.69

-1.55

-0.25

-0.43

-4.59

ITGB4

1.88

-2.73

-4.53

2.11

-3.98

-5.43

4.61

FOXO3

-1.29

-0.78

-1.85

-1.29

-0.45

-1.85

-25.32

-5.90

-79.07

RHOB

1.61

1.54

4.07

0.99

0.87

3.84

-1.95

1.21

4.58

13.00 11.41

20.79

4.60

6.13

6.13

1.32

2.00

1.97

GLUD1

-2.78

-2.66

-2.05

-2.68

-2.76

-2.76

-3.39

-2.01

-2.35

GFPT2

-1.28

-1.18

-2.47 -20.00 -1.76

-1.76

-26.72

-2.22

-8.00

ALDH5A1

5317.75 3630.12 2442.26

1119.78 288.73 140.49
1.19

-4.86

-17.60 -161.43

Table 4.12: Comparison of the fold changes in gene expression of selected genes
detected by microarray, RNA-Seq and qRT-PCR. The values represent the fold
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changes in MCF10.DCIS, SUM102 and SUM225 compared to expression in MCF10A.
The values in the table are Log2(Fold Change), positive value indicates up-regulated,
negative value indicates down-regulated.
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CHAPTER 5

ALDH5A1, A KEY ENZYME OF GLUTAMATE METABOLIC PATHWAY, PROMOTES
CELL GROWTH AND PROLIFERATION IN VARIOUS MODELS OF DUCTAL
CARCINOMA IN SITU

5.1 BACKGROUND AND RATIONALE

5.1.1 Glutamate metabolism in cancer
The cancer cells face a major bio-energetic and bio-synthetic challenge to meet the
ever increasing demands of proliferating cells. To maintain continual supply of energy
for growth and proliferation, the cancer cells undergo metabolic reprogramming wherein
they avoid oxidative phosphorylation and metabolize glucose by aerobic glycolysis even
in the presence of available oxygen. This phenomenon, known as ‘Warburg effect’ has
been long known to researchers and was observed in early 1950s. In the last decade,
various studies have reported another important alteration in cancer cellular metabolism
that is the conversion of glutamine into intermediates for other bio-synthetic pathways.
Glutamine serves as a source of reduced nitrogen, which is required by the
proliferating cancer cells to produce nucleotides and non-essential amino acids.
Glutamine metabolism was observed to be a robust source of Kreb’s cycle
intermediates, NADPH and non essential amino acid pools in glioblastoma cells
(DeBerardinis, Mancuso et al. 2007). Targeting elevated glutaminase activity by small
molecule inhibitor, 968, inhibits oncogenic transformation in breast cancer cells (Wang,

118
Erickson et al. 2010). Evidence has emerged that glutamate, the breakdown product of
glutamine, also acts as a signal mediator in malignant progression. The excitatory
neurotransmitter has been known to regulate the growth and proliferation of neurons,
however the peripheral expression of glutamate receptors points towards other diverse
biological roles that glutamate may have, apart from its neurotransmitter function.
Studies have indicated the presence of glutamate receptors in various cancers of
peripheral tissues such as melanoma (Namkoong, Shin et al. 2007), head and neck
(Haas, Linecker et al. 2010), pancreatic ductal adenocarcinoma (Herner, Sauliunaite et
al. 2011), advanced squamous cell carcinoma of larynx (Stepulak, Luksch et al. 2011)
and triple negative breast cancer (Speyer, Smith et al. 2011).

Aberrant glutamate

signaling was recently reported as most significant metabolic pathway in melanoma
(Wei, Walia et al. 2011).

Although a link between glutamate metabolism and

premalignant breast disease would be a novel connection in the context of DCIS,
metabolomic profiling of gastric cancer metastases also identified associations with
glutamate metabolism (Chen, Tang et al. 2010).
In the light of the published studies and our gene expression profiling studies by
multiple tools, we sought to further investigate the role of, one of the significantly altered
pathway associated with the differentially expressed genes in DCIS i.e. glutamate
metabolism, in promoting premalignant progression.

5.1.2 ALDH5A1 as a Novel Potential Target
Among the several members of glutamate metabolic pathway (such as aldehyde
dehydrogenase 5 family member 1; ALDH5A1, glutamine–fructose-6-phosphate
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transaminase 2; GFPT2, glutamate dehydrogenase 1; GLUD1, and glutamate ammonia
ligase; GLUL) identified in our list of differentially expressed genes in DCIS, we chose to
focus on ALDH5A1. It was selected as an initial target for detailed investigation for
several reasons. First, there was a strong gain of expression in all three models of
DCIS that was revealed by microarray, RNA-Seq and confirmed by qRT-PCR. Second,
ALDH5A1 represented a novel transcript that had not previously been associated with
breast cancer.

Third, there is established pharmacology for inhibition of ALDH5A1

through two FDA-approved drugs (disulfiram [DSF] (Hellstrom and Tottmar 1982) and
valproic acid [VPA] (van der Laan, de Boer et al. 1979). Both are known to be safe for
chronic use in patients with other disorders but have not previously been considered in
the context of DCIS.

5.1.3 Experimental Strategy
If the protein expressed by the over expressed gene contributes to a major metabolic
pathway or is a key enzyme in biochemical process, then inhibition of its activity should
lead to change in cell growth and proliferative properties. Based on this rationale, we
used different experimental approaches to manipulate the expression levels of
ALDH5A1 in order to establish the functional significance of its increased expression in
the models of DCIS.
We first determined the expression levels of ALDH5A1 at protein level and then
employed pharmacological inhibition of ALDH5A1 with different commercially available
inhibitors.

We targeted inhibition of ALDH5A1 by disulfiram, valproic acid and 4-
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hydroxybenzaldehyde or glutamate release by riluzole in the 3D rBM overlay cultures of
DCIS models (MCF10.DCIS, SUM102 and SUM225) and MCF10A.

5.2 RESULTS

5.2.1 Increased ALDH5A1 protein expression in all models of DCIS
Since changes in mRNA level are not always reflective of changes in protein
expression, so we determined the level of ALDH5A1 protein in MCF10.DCIS, SUM102,
SUM225 and MCF10A models by immunoblotting. We observed increased expression
of ALDH5A1 in all three models of DCIS in comparison to the MCF10A model (Figure
5.1).

5.2.2 Pharmacological Inhibition of ALDH5A1

5.2.2.1 Effect on cell survival and proliferation
Next, we sought to determine the effect of treatment of different drugs, on the survival
and proliferation of MCF10A cells and the three models of DCIS by an adaptation of
tetrazolium based MTT assay for 3D culture. The cells in culture were either treated
with varying concentrations of the individual drug or with the vehicle as control. We also
included doxorubicin as a positive control in all the assays.

5.2.2.1.1 Treatment with disulfiram
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Disulfiram (DSF) is a broad spectrum and irreversible inhibitor of many isozymes in
the aldehyde dehydrogenase family (Hellstrom and Tottmar 1982). Treatment with DSF
significantly inhibited proliferation of 3D rBM overlay cultures of MCF10.DCIS, SUM102
and SUM225, but had only a modest effect on 3D rBM overlay cultures of MCF10A
(Figure 5.2). For example, a concentration of 20 µM DSF significantly (p < 0.001)
reduced the proliferation of MCF10.DCIS, SUM102 and SUM225 cultures. The GI50
values (the concentration of drug that produces 50% inhibition of cell growth) for
MCF10.DCIS, SUM102 and SUM225 were 4.8 µM, 9.3 µM and 11.6 µM, respectively,
whereas the GI50 value for MCF10A was 56.9 µM.

5.2.2.1.2 Treatment with riluzole
Similar to the sensitivity pattern exhibited by the DCIS models to disulfiram
(MCF10.DCIS > SUM102 > SUM225), we observed that MCF10.DCIS model was more
sensitive to the growth inhibitory effect of riluzole than the other two SUM models
(Figure 5.3). The GI50 value for riluzole in MCF10.DCIS was 10.7 µM whereas the GI50
values for SUM102 and SUM225 were 20.2 µM and 23.4 µM respectively. However,
there was no significant difference in the growth inhibitory effect on SUM102, SUM225
and MCF10A (GI50 21.3 µM).

5.2.2.1.3 Treatment with valproic acid
Valproic acid (VPA) is a selective blocker of the ALDH5A1 isoform (van der Laan, de
Boer et al. 1979) that is increased in the three DCIS models. VPA is also an inhibitor of
the histone deacetylases (Gottlicher, Minucci et al. 2001; Phiel, Zhang et al. 2001; Eyal,
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Yagen et al. 2004). Treatment with VPA had a minimal effect on the proliferation of
MCF10A 3D rBM overlay cultures at any of the doses tested, but inhibited proliferation
of MCF10.DCIS, SUM102, and SUM225 3D rBM overlay cultures in a dose-dependent
manner (p < 0.05) (Figure 5.4).

In contrast to our observation with disulfiram and

riluzole, SUM102 had greater sensitivity to growth inhibition by valproic acid followed in
order by MCF10.DCIS and SUM225.

5.2.2.2 Effect on cellular morphology
To further evaluate, whether treatment with the above drugs can affect the
morphology of MCF10A and DCIS models as well, we performed imaging of the cells
grown on Cultrex pre-coated coverslips and cultured in 3D overlay cultures in the
presence of varying concentrations of the inhibitors or vehicle as control.

5.2.2.2.1 Treatment with riluzole
Since in the cell survival and proliferation assays, we observed that riluzole had
significant effect of MCF10.DCIS model versus a modest effect on proliferation of the
two SUM models, here we focused on the morphological analyses of MCF10.DCIS and
MCF10A structures. However, in addition to MCF10.DCIS, we also tested the effect of
riluzole on the MCF10.AT1 variant, which is an intermediate in the progression series
from MCF10A and MCF10.DCIS and represents atypical hyperplasia and also on MDAMB-231 cells, which represent invasive breast cancer. The purpose to include the preDCIS and the post-DCIS stages was to determine whether the effect of riluzole is
specific to MCF10.DCIS only or it has a wider spectrum of effect.
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We observed that treatment with riluzole significantly inhibited the growth and altered
the morphology of MCF10.DCIS and MCF10.AT1 structures at the concentration of 10
µM (and above). The control MCF10.DCIS structures showed dysplastic growth and
the control MCF10.AT1 cells formed hyper-plastic structures lacking any lumen.
However, the riluzole treated MCF10.DCIS structures looked growth inhibited and less
irregular. Similarly, the riluzole treated MCF10.AT1 structures were smaller in size as
compared to control. The treatment, however, did not show any observable effect on
the MCF10A spheroids, which looked similar to the control (Figure 5.5). Furthermore,
MDA-MB-231 cells did not exhibit any alteration in morphology upon treatment with
riluzole.

In order to determine whether riluzole has any effect on the survival and

proliferation of MDA-MB-231 cells, we then performed MTT assay.

As observed for

morphological changes, the treatment had no significant effect on growth and
proliferation of these cells (data not shown).
Next, with the aim to quantify the changes induced by riluzole treatment on the
MCF10.DCIS, MCF10.AT1 and MCF10A structures, we performed morphometric
analysis of the above structures.

Since the MDA-MB-231 cells grow as stellate

projections bridging multiple cell colonies, the evaluation could not be performed in
those structures. The analysis showed that riluzole had modest effect on the growth of
the MCF10A spheroids whereas it showed concentration dependent reduction in size
for both MCF10.DCIS and MCF10.AT1 structures. The size determination of spheroids
was performed following a blinded protocol by an undergraduate student in the
laboratory.
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5.2.2.2.2 Treatment with disulfiram
We then investigated whether disulfiram has any impact on the morphology of
MCF10A and MCF10.DCIS structures.

Herein, in addition to MCF10A and

MCF10.DCIS, we included MCF10.Ca1d cells, which represent invasive breast cancer
and is the next stage of MCF10.DCIS in the progression series. We observed that
disulfiram significantly inhibited the growth of MCF10.DCIS and MCF10.Ca1d structures
as compared to the growth of MCF10A spheroids. The control MCF10.DCIS structures
exhibited hyper-plastic growth with irregular morphology whereas the control MCF10A
structures showed typical acinar morphology.

The control MCF10.Ca1d cells

proliferated as large structures exhibiting invasive phenotype. Treatment with disulfiram
strongly inhibited growth and proliferation of both MCF10.DCIS and MCF10.Ca1d while
having a scant effect on MCF10A (Figure 5.6).

5.2.2.2.3 Treatment with 4-hydroxybenzaldehyde
Next, we sought to investigate the treatment effect of another inhibitor of ALDH5A1,
4-hydroxybenzaldehyde, upon growth and morphology of MCF10A, MCF10.DCIS and
MCF10.Ca1d cells. The treatment resulted in inhibition of proliferation of MCF10.DCIS
and MCF10.Ca1d structures whereas there was lack of any noticeable effect on
MCF10A spheroids. The treated MCF10A spheroids had the normal acinar structure
with similar size as that of control spheroids.

However, the treated MCF10.DCIS

structures were smaller in size and MCF10.Ca1d structures showed significant growth
inhibition (Figure 5.7). We then evaluated the effect of 4-hydroxybenzaldehyde on the
survival and proliferation of MCF10A and MCF10.DCIS cells using MTT assay. The
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MTT results however did not show any significant effect on survival and proliferation of
either MCF10A or MCF10.DCIS cells.

5.2.2.2.4 Treatment of DCIS variants with DSF and VPA
As an independent assay for effects on cell growth, we developed variants of
MCF10.DCIS and SUM102 cells that constitutively expresses monomeric red
fluorescent protein (mRFP) and treated 3D rBM overlay cultures of these cells. The
results show the dysplastic growth of the control and vehicle-treated MCF10.DCISmRFP and SUM102-mRFP cells over a period of eight days. This growth is essentially
terminated by inclusion of DSF at ≥ 20 µM (Figures 5.8 and 5.9A). We also tested VPA
against the SUM102-mRFP cells and found that ≥ 0.1 mM was sufficient to reduce their
proliferation (Figure 5.9B). To test whether these growth inhibitory effects of DSF and
VPA were reversible, we re-plated the cells in fresh media without drug and assayed
their ability to re-grow over 10 days (Figure 5.10). The SUM102-mRFP cells that had
been treated with 20 or 50 µM DSF showed no ability to re-grow, whereas those that
had been treated with 5 µM DSF showed minimal re-growth as compared to control,
vehicle-treated cells. Treatment with as little as 0.1 mM VPA was sufficient to almost
completely block re-growth.

5.3 DISCUSSION
From among the group of differentially expressed gene products in the DCIS models
that are involved in glutamate metabolism, we selected ALDH5A1 due to its novelty in
the context of breast cancer and status as an established druggable target. The gene
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product of ALDH5A1, also known as succinic semi-aldehyde dehydrogenase (SSDH), is
involved in the catabolism of neurotransmitter 4-aminobutyric acid (GABA) and is highly
expressed in brain. ALDH5A1 belongs to the superfamily of aldehyde dehydrogenases
(ALDHs) that oxidize aldehydes to the corresponding carboxylic acids. Very little is
known about ALDH5A1 with regard to cancer, beyond an observation in renal cell
carcinoma cells that it is regulated by hepatocyte nuclear factor 4alpha (Lucas, Grigo et
al. 2005).
In contrast, elevated activity of the ALDHs 1A2, 1A3, 1A7, 3A1, 4A1, 5A1, 6 and 9A1
has been reported in stem cells (Muzio, Maggiora et al. 2012). Increased activity of
ALDH1A1 has been observed in the stem cell populations of multiple myeloma, acute
myeloid leukemia and malignant mammary cells (Pearce, Taussig et al. 2005; Ginestier,
Hur et al. 2007). Breast cancers with stem cells having high expression of ALDH1A1
have biologically aggressive phenotypes and poor prognoses (Morimoto, Kim et al.
2009). Down regulation of ALDH1A1 and ALDH3A1 has been shown to reduce cell
growth and motility in lung cancer cells (Moreb, Baker et al. 2008). ALDH3A2 is one of
the 35-gene signature that is reported to discriminate between well- and poorly
differentiated DCIS (Hannemann, Velds et al. 2006). Here, in this chapter, we aimed to
determine the significance of many fold increase in ALDH5A1 expression in ductal
carcinoma in situ that we observed in our expression profiling data and how that
contributes towards premalignant progression.
Whole genome expression analysis by microarrays and sequencing showed
significant increases in ALDH5A1 expression in the DCIS models that was validated by
both qRT-PCR and immunoblotting.

Meta-analysis of normalized gene expression
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profiles in the GeneSapiens "body-wide" microarray database reveals that the median
level of ALDH5A1 expression is significantly higher in certain cancers (particularly
glioma and some leukemias and lymphomas). In the group of breast and reproductive
cancers, the median expression of ALDH5A1 remains low. Notably, there are outliers of
breast cancers classified as ductal and classified as not-otherwise-specified (which
would include DCIS and IDC, respectively) in which ALDH5A1 is increased in
expression (Figure 5.11).

5.3.1 Studies with Disulfiram
The studies with disulfiram (DSF) were undertaken in view of its potential to
irreversibly inhibit aldehyde dehydrogenases and notably ability to block ALDH5A1 in
brain slices (Hellstrom and Tottmar 1982). DSF has been used clinically for several
decades as a deterrent to alcohol consumption and has recently emerged as a potential
cancer drug. Its antitumor activity has been previously reported in both in vitro and in
xenograft studies of breast cancer cell lines (Chen, Cui et al. 2006; Wickstrom,
Danielsson et al. 2007), but the possibility that this activity could be due to inhibition of
the ALDH5A1 isoform was not previously considered. We observed that DSF at low
micromolar concentrations was effective in inhibiting proliferation of all three DCIS
models, while having negligible effect on the MCF10A model of normal breast epithelial
cells. Notably, 20 µM DSF had a significant effect on all the DCIS models in 3D rBM
culture.

This concentration has previously been shown to have no effect on

MCF10.DCIS cells grown in conventional 2D cell culture unless supplemented with 20
µM CuCl2 to allow inhibition of the proteasome. DSF forms complex with the available
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copper and the drug-metal complex then targets the proteasome resulting in
accumulation of tumor suppressor proteins and induction of apoptotic cell death (Chen,
Cui et al. 2006). In the present study, the copper concentration in the medium used for
3D culture was approximately 1 nM. Hence, the observed effect on proliferation is
unlikely to be due to inhibition of proteasomal activity.

5.3.2 Studies with Riluzole
Riluzole is an FDA-approved drug for the treatment of amyotrophic lateral sclerosis
(ALS), which is a motor neuron disease resulting from neurodegeneration in the central
and peripheral nervous system. Riluzole functions as a glutaminergic modulating agent
with complex mechanisms of action. It inhibits release of glutamate at the presynaptic
nerve terminals by blocking voltage gated sodium channels (Urbani and Belluzzi 2000).
It also reduces the glutamate vesicle fusion with the pre-synaptic cell membrane thus
inhibiting glutamate release (Huang, Song et al. 1997; Wang, Wang et al. 2004).
Treatment with riluzole was shown to decrease the glutamatergic neuronal excitation in
SH-SY5Y human neuroblastoma cells (Arun, Moffett et al. 2010).

Riluzole also

functions in part by blocking the metabotropic glutamate receptor mGluR1 (Speyer,
Smith et al. 2012).

Riluzole was able to block proliferation of melanoma cell lines

expressing mGluR1 (Namkoong, Shin et al. 2007) as well as suppress melanoma
migration, invasion and colony formation (Le, Chan et al. 2010). Another study showed
that the combining multi-kinase inhibitor Sorafenib with Riluzole effectively suppressed
proliferation in melanoma cells (Lee, Wall et al. 2011) .
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Based on these findings, we chose riluzole to target glutamate signaling in our DCIS
models and observe the effect of its treatment on cellular proliferation. We found in our
study that riluzole inhibited the proliferation of MCF10.DCIS whereas it had less
significant effect on the MCF10A. Furthermore, we observed that riluzole treatment
altered the morphology and reduced the size of MCF10.AT1 and MCF10.DCIS
structures while having no observable effect on MCF10A spheroids at the same dose.
Our investigations of riluzole in premalignant breast gain support from a recent study
that reported the effectiveness of riluzole in reducing tumor volume in mice bearing
triple negative breast cancer xenografts (Speyer, Smith et al. 2011).
We also observed in our study that riluzole treatment at low dose did not have
significant effect on cell proliferation of SUM102 and SUM225 as that observed in
MCF10.DCIS. This may be attributed to the different levels of expression of mGluR1
receptors in the different models of DCIS.

Further investigation into the levels of

metabotropic glutamate receptors in the different DCIS models may address the
different sensitivities of these models to riluzole treatment.
The lack of any effect on MDA-MB-231 cell proliferation in our study is in contrast to
the findings of Speyer et al. wherein they observed significant inhibition of proliferation
of these cells by riluzole (Speyer, Smith et al. 2011).

A plausible explanation of this

discrepancy lies in the doses used for the experiments. This inhibitory effect on cellular
proliferation was observed at a much higher dose of riluzole (at 50µM) in their study
whereas the highest dose used in our study was 30 µM. Another notable observation is
that at the effective concentration of 50µM, they also observed inhibition of proliferation
of non-transformed mammary epithelial cells. In the present study, however, we have
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observed differential effect of riluzole at a low dose (10 µM) on proliferation of
MCF10.DCIS and MCF10A cells. Overall, these findings are encouraging and suggest
that riluzole may be a promising new approach in the treatment of DCIS either as a
single agent or in combination therapy.

5.3.3 Studies with 4-hydroxybenzaldehyde
4-Hydroxybenzaldehyde (HBA) is a competitive inhibitor of ALDH5A1 (Rivett and
Tipton 1981) and is a major active constituent of Gastrodiae Rhizoma, a traditional
herbal medicine used in the treatment of migraine, epilepsy and several neurological
disorders (Tao, Yuan et al. 2006). With its given mechanism of ALDH5A1 inhibition, we
tested this compound in our DCIS models to observe the effect of its treatment on cell
survival, proliferation and morphology.

It was intriguing to observe that whereas it

showed significant inhibition of growth with reduction in size of the MCF10.DCIS and
MCF10.Ca1d structures in the morphology studies, it did not show any significant
treatment effect in the cell survival and proliferation assays. This incongruity between
the observations may be explained by the variation in the duration of treatments for the
morphology and cell proliferation studies. The cells were treated with HBA for a period
of 8 days in the morphology assays whereas for cell proliferation assays they were
treated for a period of 72 hours.

This might well explain the observed difference

between the treatment effects of 4-hydroxybenzaldehyde on cell growth, morphology
and cell proliferation.
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5.3.4 Studies with valproic acid
Valproic acid (VPA) is a widely used drug in the treatment of epileptic seizures and
mania in bipolar disorder.

Other approved indications include the treatment of

neuropathic pain and as prophylaxis for migraine. Valproic acid exerts its action by
potentiating the inhibitory effects of neurotransmitter GABA by several mechanisms. It
inhibits GABA degradation and turnover and increases its synthesis (Johannessen
2000); (Johannessen and Johannessen 2003); (Owens and Nemeroff 2003). VPA was
observed to affect the removal of glutamate in the synaptic cleft by up-regulating the
glial transporter, glutamate-aspartate transporter (GLAST), and decreasing GABA
transport resulting in increased concentrations of GABA (Ueda and Willmore 2000).
VPA inhibits ALDH5A1 with a Ki of ~ 0.5 mM (Whittle and Turner 1981), and this
activity is important to its anti-seizure activity (Johannessen 2000). More recently VPA
has also been found to inhibit histone deacetylases with similar potency (Gottlicher,
Minucci et al. 2001; Phiel, Zhang et al. 2001; Eyal, Yagen et al. 2004). Notably, the
serum concentration of VPA in patients under standard chronic therapy is 0.35 - 0.7 mM
(Phiel, Zhang et al. 2001). We have observed in our study that VPA, in a concentration
dependent manner, inhibits proliferation in all three models of DCIS whereas having a
minimal effect on the non-tumorigenic breast epithelial cells. The concentrations of VPA
that effectively inhibit DCIS proliferation are within the therapeutic range for VPA
therapy in humans (Phiel, Zhang et al. 2001).

The discovery of VPA inhibition of

histone deacetylases has provided a rationale for studies to test whether it has anticancer effects, including in the context of breast cancer [e.g., ClinicalTrials.gov:
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NCT01010854]. The results from our study suggest that inhibition of ALDH5A1 may
contribute to its anti-tumorigenic activity.

5.3.5 Conclusions
To summarize, ALDH5A1, an enzyme of glutamate metabolism, has not previously
been linked to DCIS. Two drugs, DSF and VPA, that target ALDH5A1 significantly
reduced proliferation in all the three DCIS models. These results taken together with
the extensive clinical experience and safety profile of both the drugs encourage further
studies for the potential repurposing in the treatment of DCIS.
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Figure 5.1: ALDH5A1 is over-expressed in DCIS models. Whole cell lysates from
3D rBM overlay cultures of MCF10A, MCF10.DCIS, SUM102 and SUM225 were probed
for ALDH5A1 (upper panel) and for GAPDH (lower panel) as a loading control.
Densitometry indicated that ALDH5A1 levels in the lysates of MCF10.DCIS, SUM102,
and SUM225 were 2.7, 3.1, and 7.3-fold over that in MCF10A in this representative
experiment. In three independent analyses of MCF10.DCIS 3D rBM cultures, the mean
increase in ALDH5A1 over control was 3.8-fold.
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Figure 5.2: Effect of disulfiram on the proliferation of MCF10A, MCF10.DCIS,
SUM102 and SUM225 models. Cells were incubated for 72 hours with the indicated
concentrations of drug or with DMSO as a vehicle control and subjected to an MTT
assay. Sigmoidal dose-response curves were plotted using nonlinear regression
analysis. Data represent the mean ± SEM of three independent experiments (each
performed in triplicate).
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Figure 5.3: Effect of riluzole on cell proliferation of MCF10A, MCF10.DCIS,
SUM102 and SUM225. Cells were cultured in Cultrex pre-coated 96 well plates for 72
hours with the indicated concentrations of riluzole or with DMSO as a vehicle control
and subjected to MTT assay. Sigmoidal dose-response curves were plotted using
nonlinear regression analysis. Data represent the mean ± SEM of three independent
experiments (each performed in triplicate).
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Figure 5.4: Effect of valproic acid on cell proliferation of MCF10A, MCF10.DCIS,
SUM102 and SUM225. Cells were incubated for 72 hours with the indicated
concentrations of valproic acid and subjected to an MTT assay. Sigmoidal doseresponse curves were plotted using nonlinear regression analysis. Data represent the
mean ± SEM of three independent experiments (each performed in triplicate).
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Figure 5.5: Treatment of MCF10A, MCF10.DCIS, MCF10.AT1 and MDA-MB-231
three dimensional overlay cultures with Riluzole. Differential interference contrast
images of MCF10A, MCF10.DCIS, MCF10.AT1 and MDA-MB-231cultured in 3D rBM
overlay culture in the presence of indicated concentrations of Riluzole or DMSO as a
vehicle control for 8 days. DIC images at 10x magnification. Results are representative
of each experiment performed in triplicates.
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Figure 5.6: Treatment of MCF10A, MCF10.DCIS and MCF10.Ca1d cells with DSF.
Differential interference contrast images of MCF10A, MCF10.DCIS and MCF10.Ca1d
cultured in 3D rBM overlay culture in the presence of indicated concentrations of
inhibitor or DMSO as a vehicle control for 8 days. DIC images at 10x magnification.
Results are representative of two independent experiments performed in duplicates.
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Figure 5.7: Treatment of MCF10A, MCF10.DCIS and MCF10.Ca1d cells with 4hydroxybenzaldehyde. Differential interference contrast images of MCF10A,
MCF10.DCIS and MCF10.Ca1d cultured in 3D rBM overlay culture in the presence of
indicated concentrations of inhibitor or ethanol as a vehicle control for 8 days. DIC
images at 10x magnification. Data are representative of results from two independent
experiments.
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Figure 5.8: Treatment of MCF10.DCIS cells that express mRFP with DSF.
Differential interference contrast (DIC) images of MCF10.DCIS-mRFP cells cultured in
3D for 8 days in the absence or presence of the indicated concentrations of DSF or
DMSO as a solvent control. DIC images at 10x magnification. Data are representative of
results from three independent experiments.
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Figure 5.9: Effect of inhibitors on 3D rBM cultures of SUM102-mRFP cells. Panel
A) DSF; Panel B) VPA. Cells were incubated for 8 days with the indicated
concentrations of drugs or with DMSO as a vehicle control and DIC images are shown.
Size bar, 90 µm.
Data are representative of results from three independent
experiments.
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Figure 5.10: Quantification of re-growth of SUM102-mRFP cells after drug
exposure. Three-dimensional rBM overlay cultures of SUM102-mRFP cells were
treated for 8 days with the indicated concentrations of VPA (upper panel) or DSF (lower
panel) or vehicle control. The cells were then harvested from the matrix and re-plated in
fresh media without inhibitors for growth in 2D over 10 days. Results shown are mean ±
SEM from three independent experiments.
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Figure 5.11: Meta-analysis of normalized gene expression profiles in the
GeneSapiens microarray database. The highlighted designations of “Breast, ductal
cancer” and “Breast carcinoma, NOS” include DCIS and IDC. The boxes represent the
quartile distribution (25-75%) range and the red horizontal lines show the median. The
plots also show 95% black whiskers and the individual outlier samples as small circles.
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CHAPTER 6
CONCLUSIONS AND PERSPECTIVES
In the present study, we attempted to identify the alterations in gene expression that
occur during the premalignant progression from normal breast to ductal carcinoma in
situ. We compared the gene expression profiles of DCIS mammary epithelial cells of
various origins with the non tumorigenic mammary epithelial cells with the aim to
elucidate significant genes and pathways underlying the premalignant transformation.
Here, we employed a novel in vitro 3D overlay culture system that simulates the in vivo
environment conditions. By using this model system, we overcame the clinical issues of
isolating the microscopic DCIS samples and were able to characterize the mammary
epithelial cells without any contamination from the stromal components. Also, we were
able to obtain high quality RNA samples from the structures harvested from 3D culture
as opposed to extraction of RNA from the formalin fixed paraffin embedded tissues that
compromises the integrity of RNA for subsequent analysis. At present, this is the first
report on gene expression analysis in DCIS using the in vitro 3D culture.
In the first part of the dissertation, we describe the identification of a common set of
differentially expressed genes in various models of DCIS (MCF10.DCIS, SUM102 and
SUM225) as compared to non malignant mammary epithelial cells (MCF10A) referred
herein as ‘normal’ by Affymetrix microarray analysis. We found that these differentially
expressed genes are associated with a number of signaling pathways such as
glutamate metabolism, IGF-1 signaling, integrin signaling and fatty acid biosynthesis,
implicated and dysregulated in various cancers.

We then validated the microarray
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findings using diverse platforms in the next chapter. This included gene expression
analysis by digital gene sequencing, next generation sequencing and real time PCR.
Here, in addition to validation, we also reported the detection of low abundance and rare
transcripts differentially expressed in DCIS. Many differentially expressed transcripts in
DCIS were found to be involved in cell-cell adhesion and cell proliferation implicating the
significance of these biological processes in premalignant progression. Furthermore,
we identified the common promoter structures by ultra high throughput sequencing that
may explain the functional regulation of different co-expressed genes in DCIS. Our
study describes the first ever application of deep sequencing technology to identify
genetic signatures and to explore the networks and pathways that underlie DCIS of the
breast.
In the final chapter of this dissertation, we describe the characterization of ALDH5A1,
an important molecular target involved in glutamate metabolic pathway that was found
to be up-regulated in all DCIS models in microarray and sequencing studies. We found
that ALDH5A1 promoted cell growth and proliferation in all the three models of DCIS.
This study is not without limitations and further studies are needed for a better
understanding of the molecular and genetic alterations that underlie the progression
from normal to premalignant DCIS stage. Establishing the role of select gene products
in driving the premalignant progression by conducting animal experiments will move this
work forward. Further characterization of the differentially expressed genes in various
patient samples like tissue microarrays will strengthen the clinical significance of our
study and may help to establish molecular markers for DCIS. Our study characterizes
the global transciptomic profile of breast epithelial cells, however, given the importance
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of interactive role of stromal cells with the tumor cells in the microenvironment, future
gene expression studies can be done with inclusion of one or more stromal components
in the 3D culture model system. This study lays down the basic foundation for such
future complex studies.
Further analysis of our deep sequencing data will be able to reveal important
information about alternative splicing events like exon skipping, new splice junctions
and novel isoforms in the DCIS. Altogether, our findings move the field forward towards
a better understanding of the gene expression changes from the normal breast
epithelium to the premalignant DCIS stage.
In conclusion, to the best of our knowledge, this is the first study to identify the
transcriptional fingerprint and regulatory pathways at the whole genome level using next
generation sequencing in the organotypic 3D overlay culture model of DCIS of the
breast.
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APPENDIX
List of 295 significantly differentially expressed genes in DCIS models

GeneID
12
125
247
250
347
348
443
633
667
715
768
810
827
924
970
972
1012
1131
1277
1280
1288
1294
1295
1308
1356
1363
1364
1435
1440
1634
1796
1805
1836
1907
1999
2239

Symbol
SERPINA3
ADH1B
ALOX15B
ALPP
APOD
APOE
ASPA
BGN
DST
C1R
CA9
CALML3
CAPN6
CD7
CD70
CD74
CDH13
CHRM3
COL1A1
COL2A1
COL4A6
COL7A1
COL8A1
COL17A1
CP
CPE
CLDN4
CSF1
CSF3
DCN
DOK1
DPT
SLC26A2
EDN2
ELF3
GPC4

DCIS_vs_MCF10A
log2Fold
Change
padj
2.441
0.000
-Inf
0.000
-3.562
0.000
-2.829
0.000
2.772
0.000
-7.323
0.000
-4.969
0.000
-6.069
0.000
-2.945
0.000
-4.216
0.000
3.369
0.000
-8.707
0.000
3.035
0.000
-4.762
0.000
-2.313
0.000
2.375
0.000
-7.113
0.000
3.020
0.000
-4.160
0.000
-5.783
0.000
-3.427
0.000
-2.576
0.000
3.055
0.000
-3.105
0.000
3.314
0.000
2.297
0.000
2.193
0.000
-3.621
0.000
-4.240
0.000
-6.528
0.000
2.379
0.000
-4.173
0.001
2.359
0.000
-2.138
0.000
2.444
0.000
2.578
0.000

SUM102_vs_MCF10A
log2Fold
Change
padj
-3.206
0.000
-Inf
0.000
-4.179
0.000
3.087
0.000
5.521
0.000
-3.308
0.000
-Inf
0.000
-8.027
0.000
-3.362
0.000
-2.270
0.000
-4.963
0.000
-3.321
0.000
-7.579
0.000
-5.703
0.000
-3.469
0.000
-3.512
0.000
-3.180
0.000
-Inf
0.000
-2.486
0.000
-3.170
0.000
-2.433
0.000
-2.491
0.000
-2.052
0.000
-4.103
0.000
-4.829
0.000
2.816
0.000
5.508
0.000
-2.563
0.000
2.743
0.000
-5.016
0.000
-3.284
0.000
-Inf
0.000
-3.389
0.000
-4.704
0.000
4.181
0.000
-2.522
0.000

SUM225_vs_MCF10A
log2Fold
Change
padj
-4.922
0.000
-Inf
0.000
2.060
0.000
-2.956
0.000
4.424
0.000
-6.379
0.000
-Inf
0.000
-5.054
0.000
-2.407
0.000
-6.984
0.000
-4.577
0.000
-7.863
0.000
-Inf
0.000
-3.582
0.000
-5.589
0.000
4.732
0.000
-8.836
0.000
-3.503
0.000
-3.065
0.000
-Inf
0.000
-7.475
0.000
-5.730
0.000
-Inf
0.000
-10.474
0.000
-4.437
0.000
4.336
0.000
4.209
0.000
-4.493
0.000
-3.372
0.000
-Inf
0.000
-4.355
0.000
-Inf
0.000
-5.882
0.000
-4.482
0.000
2.364
0.000
-Inf
0.000
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2261
2281
2308
2525
2532
2535
2628
2706
2737
2741
3092
3176
3204
3382
3399
3492
3635
3691
3745
3853
3854
3855
3861
3912
3934
4017
4064
4129
4241
4313
4493
4684
4776
4811
4915
5063
5067
5099
5137
5155
5176
5376
5603

FGFR3
FKBP1B
FOXO1
FUT3
DARC
FZD2
GATM
GJB2
GLI3
GLRA1
HIP1
HNMT
HOXA7
ICA1
ID3
IGH@
INPP5D
ITGB4
KCNB1
KRT6A
KRT6B
KRT7
KRT14
LAMB1
LCN2
LOXL2
CD180
MAOB
MFI2
MMP2
MT1E
NCAM1
NFATC4
NID1
NTRK2
PAK3
CNTN3
PCDH7
PDE1C
PDGFB
SERPINF1
PMP22
MAPK13

-7.542
-3.561
-2.927
2.889
-Inf
-2.428
3.253
3.192
-3.090
-3.123
-3.918
2.763
3.178
2.135
-3.951
-Inf
-3.269
2.208
-2.651
-2.053
2.823
2.694
-7.433
-3.809
2.234
3.013
2.852
2.017
2.698
2.826
-6.242
2.979
2.660
-Inf
2.726
2.061
3.073
-5.215
2.669
2.412
-3.726
2.942
2.001

0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000

-3.606
-3.721
-2.732
4.143
-5.146
-2.542
-Inf
4.106
-2.058
-4.439
-2.218
2.172
3.372
2.625
-2.384
-Inf
-2.288
-3.660
-5.289
2.360
2.275
4.091
-2.679
-3.968
6.333
-3.312
-Inf
-2.860
-4.864
-5.679
-3.778
-3.705
3.424
-6.183
-Inf
-Inf
-2.530
-2.127
-Inf
2.162
-2.540
-2.898
2.580

0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.001
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.001
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.001
0.000
0.000
0.000
0.000
0.000
0.000

-2.700
-Inf
-3.423
4.379
-Inf
-2.804
5.273
-2.180
-3.839
-2.372
-3.897
3.821
2.373
4.032
-2.785
-2.723
-5.240
-6.051
-5.904
-4.099
-3.748
3.736
-9.086
-7.238
3.043
-3.514
-Inf
-Inf
-4.476
-5.295
-8.621
-Inf
3.346
-Inf
-Inf
-3.541
-Inf
-2.353
-Inf
3.569
-5.328
-Inf
3.463

0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
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5654
5909
5990
5997
6090
6271
6286
6319
6364
6376
6398
6441
6542
6947
7045
7049
7078
7092
7097
7161
7291
7368
7570
7704
7915
8343
8515
8645
8698
8706
8839
8991
9080
9227
9241
9289
9435
9586
9610
9651
9672
9750
9805

HTRA1
RAP1GAP
RFX2
RGS2
RNY5
S100A1
S100P
SCD
CCL20
CX3CL1
SECTM1
SFTPD
SLC7A2
TCN1
TGFBI
TGFBR3
TIMP3
TLL1
TLR2
TP73
TWIST1
UGT8
ZNF22
ZBTB16
ALDH5A1
HIST1H2BF
ITGA10
KCNK5
S1PR4
B3GALNT1
WISP2
SELENBP1
CLDN9
LRAT
NOG
GPR56
CHST2
CREB5
RIN1
PLCH2
SDC3
FAM65B
SCRN1

-3.437
2.261
-4.368
-2.757
-Inf
2.899
2.435
2.367
3.329
2.963
-4.361
-2.912
-Inf
2.468
-5.095
-3.143
-4.420
-Inf
-4.569
-4.437
-2.128
2.705
2.191
-7.287
2.146
2.711
2.571
2.642
-2.036
2.925
-6.739
-2.130
2.809
3.034
2.033
2.687
-3.568
3.117
-2.134
-4.224
-2.707
-5.709
2.248

0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.001
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000

-3.719
2.015
-2.052
3.436
-Inf
-4.376
4.158
2.063
5.673
-4.851
-3.122
-2.182
-2.339
-2.744
-6.042
-6.830
-3.086
-3.983
3.708
-4.972
-2.631
-Inf
2.647
-4.061
2.688
3.648
-4.867
-2.994
-5.305
2.626
-6.653
-2.666
3.066
-3.331
-2.739
2.396
-2.323
4.440
-2.229
-3.027
-5.151
-2.481
3.101

0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.001
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000

-3.027
6.110
-2.083
-3.013
-2.742
-2.759
2.803
3.612
3.656
6.709
-4.039
-2.379
-4.542
-4.258
-11.619
-4.613
-5.973
-Inf
2.803
-2.587
-8.800
-3.861
3.397
-4.390
2.968
3.230
-5.428
-2.380
-Inf
4.365
-3.848
2.362
4.958
-2.678
-2.349
3.387
-4.735
3.586
-5.315
-5.950
-2.433
-3.851
2.684

0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000

150
9839
9843
9976
10170
10232
10388
10398
10409
10544
10551
10630
10631
10656
10816
10942
11341
22997
23043
23087
23105
23157
23255
23284
23329
23507
23555
23767
25791
25841
26018
26050
26227
26287
26577
26579
26771
27065
27134
27293
28513
28999
29841
51170

ZEB2
HEPH
CLEC2B
DHRS9
MSLN
SYCP2
MYL9
BASP1
PROCR
AGR2
PDPN
POSTN
KHDRBS3
SPINT3
PRSS21
SCRG1
IGSF9B
TNIK
TRIM35
FSTL4
SEPT6
KIAA0802
LPHN3
TBC1D30
LRRC8B
TSPAN15
FLRT3
NGEF
ABTB2
LRIG1
SLITRK5
PHGDH
ANKRD2
PCOLCE2
MYEOV
SNORD102
D4S234E
TJP3
SMPDL3B
CDH19
KLF15
GRHL1
HSD17B11

-3.903
2.931
-2.019
2.139
-6.636
2.147
-3.996
-3.345
-2.226
3.043
-Inf
-4.984
2.442
-Inf
2.541
3.036
-3.340
-2.178
-2.654
-Inf
2.686
-2.025
2.581
2.240
2.530
2.187
-2.666
2.779
2.019
2.309
-4.489
2.435
-3.547
2.816
3.023
-Inf
-2.525
2.058
2.346
3.124
-2.775
2.110
-3.063

0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000

-3.420
-3.106
-2.691
2.184
-4.824
-3.067
-7.321
3.669
-3.217
5.173
-3.270
-4.897
-6.158
-Inf
-2.337
-Inf
-7.496
-3.511
-2.311
-Inf
3.911
-2.107
-Inf
2.995
2.139
2.668
-3.197
-2.984
2.541
-2.865
-Inf
2.410
-4.160
-5.106
2.768
-Inf
-3.951
3.298
2.777
-Inf
-Inf
4.940
-2.196

0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.001
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000

-4.028
-4.304
-3.807
-3.197
-6.784
3.298
-3.871
-2.612
-7.960
6.818
-Inf
-Inf
-2.654
-Inf
-2.983
-Inf
-7.112
-3.899
-4.489
-2.512
4.444
-2.305
-4.298
3.613
3.515
4.121
-4.825
-2.309
2.685
2.113
-Inf
5.083
-Inf
-Inf
-3.461
-Inf
-6.959
2.751
3.074
-Inf
-6.105
2.827
-Inf

0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.001
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000

151
51330
53947
54437
54453
54504
54831
54836
54845
54863
55224
55349
55653
56125
56241
57111
57484
57604
57639
57863
58473
64063
64218
65987
65989
65997
66002
78995
79094
79148
79156
79603
79783
79919
79977
80023
80117
80176
81606
81623
81848
83700
84109
84707

TNFRSF12A
A4GALT
SEMA5B
RIN2
CPVL
BEST2
BSPRY
ESRP1
C9orf167
ETNK2
CHDH
BCAS4
PCDHB11
SUSD2
RAB25
RNF150
C8orf79
CCDC146
CADM3
PLEKHB1
PRSS22
SEMA4A
KCTD14
DLK2
RASL11B
CYP4F12
C17orf53
CHAC1
MMP28
PLEKHF1
LASS4
C7orf10
C2orf54
GRHL2
NRSN2
ARL14
SPSB1
LBH
DEFB126
SPRY4
JAM3
QRFPR
BEX2

2.027
-4.483
-5.613
-2.088
2.730
-4.024
3.081
2.763
-3.087
-5.539
2.685
-2.511
-2.292
2.512
2.966
2.770
-4.266
-2.406
-7.274
2.936
2.451
2.161
2.569
-3.014
-6.031
-6.324
-2.335
2.283
-3.160
2.223
-Inf
-2.955
2.445
3.063
2.600
-5.054
-2.947
-Inf
-Inf
2.789
-4.476
2.464
2.804

0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000

2.502
-8.590
-3.554
-2.021
-2.780
-3.540
3.141
3.781
2.709
-4.243
-3.598
-2.115
-4.940
-2.093
2.620
-4.221
-4.672
-2.355
-7.246
-3.621
4.864
2.385
-4.803
-5.486
-3.651
-3.236
-2.662
5.749
-2.342
2.515
-2.613
-2.164
5.541
4.669
-4.542
-3.440
-2.522
-2.638
-Inf
3.017
-5.389
-3.506
2.424

0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000

2.144
-8.787
-Inf
-2.507
-4.335
-4.737
3.034
3.845
-2.732
-3.650
3.350
-3.019
-Inf
3.972
2.220
-Inf
-4.877
-2.380
-Inf
-2.973
3.057
4.289
-3.007
-4.097
-5.573
-3.627
-2.094
4.450
-8.417
3.162
2.624
-6.571
4.158
5.573
3.114
-4.234
-2.585
-4.530
-Inf
4.688
-3.996
-Inf
4.008

0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000

152
84913
84940
84969
89932
90226
90362
90525
92126
94162
114088
114783
114897
117195
117248
120892
124930
124975
126433
128218
130497
135398
144195
144501
146439
146802
147920
151473
153346
161291
163259
165545
200634
200879
221400
223075
255189
257000
283174
284759
285195
285944
286527
340359

ATOH8
CORO6
TOX2
PAPLN
UCN2
FAM110B
SHF
DSEL
SNORD38A
TRIM9
LMTK3
C1QTNF1
MRGPRX3
GALNTL2
LRRK2
ANKRD13B
GGT6
FBXO27
TMEM125
OSR1
C6orf141
SLC2A14
KRT80
CCDC64B
SLC47A2
IGFL2
SLC16A14
LOC153346
TMEM30B
DENND2C
DQX1
KRTCAP3
LIPH
TDRD6
CCDC129
PLA2G4F
PLAC2
LOC283174
SIRPB2
SLC9A9
LOC285944
TMSB15B
KLHL38

-6.495
-4.903
-4.599
-4.569
-3.376
-Inf
2.716
-3.212
-Inf
2.939
2.533
2.579
2.793
-3.208
-2.211
-2.138
2.480
3.614
2.468
2.896
-2.378
-3.762
2.732
2.103
-4.069
-Inf
3.631
-2.139
2.547
-2.984
-2.443
2.046
2.122
-2.529
2.874
-5.278
-3.129
-3.309
-3.718
-5.110
2.970
-3.789
-6.074

0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000

-Inf
-2.513
-5.204
-3.066
-3.025
-4.142
-4.094
-4.991
-Inf
-Inf
2.532
2.253
3.479
-3.031
-2.310
-2.878
3.418
3.573
2.061
-5.165
-2.487
-4.705
5.486
4.315
-6.340
-2.562
4.073
-3.796
2.036
2.142
-3.583
-4.032
4.346
-5.067
-Inf
-2.672
3.075
-Inf
-3.657
-2.987
3.405
-4.523
-3.846

0.000
0.000
0.000
0.000
0.000
0.001
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000

-2.271
-5.036
-Inf
-3.549
-Inf
-4.328
-4.007
-6.511
-Inf
-Inf
4.652
-4.141
-4.783
-6.024
-2.872
-4.047
3.922
3.765
3.430
-6.362
-5.232
-Inf
3.144
4.032
-4.536
-Inf
6.321
-2.380
4.281
-3.336
-5.055
-4.426
5.099
-5.275
-Inf
-5.253
2.297
-8.498
-5.024
-7.565
2.302
-Inf
-3.402

0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000

153
341640
388611
400945
401827
441869
642587
643965
645027
646543
692111
692198
727936
728196
100128031
100128186
100128501
100128703
100128770
100128789
100129500
100130131
100131825
100132240
100192386
100286923
100287089
100287407
100287558
100288023
100288314
100288409
100288670
100288776
100288925
100289165
100289344
100289437
100289488
100289567
100289603
100289660
100290920
100293045

FREM2
CD164L2
FLJ41481
MSLNL
hCG_20426
LOC642587
TMEM88B
EVPLL
LOC646543
SNORD71
SNORD78
GLT8D4
LOC728196
LOC100128031
LOC100128186
LOC100128501
LOC100128703
LOC100128770
LOC100128789
LOC100129500
LOC100130131
LOC100131825
LOC100132240
FLJ16779
LOC100286923
LOC100287089
LOC100287407
LOC100287558
LOC100288023
LOC100288314
LOC100288409
LOC100288670
LOC100288776
LOC100288925
LOC100289165
LOC100289344
LOC100289437
LOC100289488
LOC100289567
LOC100289603
LOC100289660
LOC100290920
LOC100293045

2.984
-4.286
-3.785
-5.539
-3.645
-4.208
-3.851
-5.270
-2.493
-2.111
-2.494
2.031
-5.172
2.076
-Inf
-4.274
2.802
2.819
4.767
-7.347
-Inf
-Inf
2.607
-4.969
-Inf
-3.047
-2.154
-Inf
-3.341
2.504
-Inf
-2.681
2.615
-Inf
-5.790
-3.842
-2.724
2.465
-3.524
-3.837
-4.173
-5.694
-2.838

0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.001
0.000
0.000

-Inf
-2.803
-Inf
-5.449
-2.587
-3.985
-2.530
-5.183
-Inf
-3.051
-2.464
-2.941
-5.142
5.421
-Inf
-2.714
-2.357
4.698
5.212
-3.416
-2.984
-Inf
-2.316
-4.939
-4.482
-2.669
-3.512
-4.770
-3.087
2.102
-2.860
-5.780
3.669
-Inf
-4.591
-Inf
-Inf
4.144
-2.549
-Inf
-Inf
-6.189
-7.650

0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000

-Inf
-3.415
-3.513
-Inf
-4.776
-6.783
-3.990
-3.378
-8.203
-3.067
-2.470
-Inf
-Inf
4.188
-Inf
-2.707
-3.554
4.696
5.226
-6.607
-3.168
-Inf
-6.213
-Inf
-3.546
-6.761
-5.293
-4.553
-3.277
3.485
-2.382
-2.276
3.610
-6.036
-4.152
-3.951
-5.107
2.317
-4.655
-Inf
-Inf
-Inf
-6.259

0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000

154
100294404 LOC100294404

-4.499

0.000

-2.776

0.000

-3.924

0.000

The values in each column represent the log2 fold change in a DCIS model over
MCF10A with adjusted p-value. “Inf” indicates that no reads mapped to that DCIS
model.
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ABSTRACT
ANALYSIS OF GENE EXPRESSION ALTERATIONS IN PREMALIGNANT
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Mammary ductal carcinoma in situ (DCIS) is being found in great numbers of women
due to the widespread use of mammography. The molecular and genetic changes
underlying the progression from normal breast tissue to DCIS are not clearly
understood. The goal of the present study was to determine gene expression changes
in different DCIS models (MCF10.DCIS, SUM102 and SUM225) in comparison to nontransformed breast epithelial cells (MCF10A) that may enable us to identify novel
markers of disease progression and potential therapeutic targets.
We cultured the cells in three dimensional (3D) overlay cultures with reconstituted
basement membrane (rBM) and subjected the extracted RNA to whole genome
expression analysis by Affymetrix GeneChip® U133A 2.0 Arrays. We found 157 genes
that were consistently differentially expressed between MCF10A and different DCIS
models. Pathway analysis showed that a subset of differentially expressed genes in
DCIS is strongly linked to glutamate metabolism and others involved in dysregulation of
various pathways such as IGF-1 signaling, integrin signaling and fatty acid biosynthesis.
To further enrich the expression data and identify low abundance transcripts we
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employed next generation sequencing (RNA-Seq) using Illumina Genome Analyzer
GAIIx.

Analysis of the sequencing data showed 295 consistently differentially

expressed transcripts in the DCIS models. We found that these differentially expressed
genes encode proteins that are associated with a number of signaling pathways such as
integrin, fibroblast growth factor and TGFβ signaling and show association with cell-cell
signaling, cell-cell adhesion and cell proliferation. We further mined our sequencing
data to explore common frameworks in the promoter regions of differentially expressed
genes. We found significant enrichment of several common frameworks present in
promoters of several genes like ELF3, CCL20, NFATC4, RAP1GAP, SPRY4 and
PDGFB. We also validated the expression data from microarray and RNA Seq with
quantitative real-time PCR (qRT-PCR) of selected differentially expressed genes.
We further characterized ALDH5A1, which encodes the enzyme aldehyde
dehydrogenase 5A1 that is involved in mitochondrial glutamate metabolism. We found
that ALDH5A1 protein is over-expressed in all three DCIS models.

Further, two

different drugs, disulfiram and valproic acid, that target ALDH5A1 significantly inhibited
growth and proliferation in the DCIS models, but had minimal effect on MCF10A.

Our

results suggest that ALDH5A1 may play an important role in DCIS and additional
studies are warranted to evaluate the potential repurposing of disulfiram and valproic
acid to treat DCIS.
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